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Abstract 
Neural tube defects are the second most common birth defect of the central 
nervous system. The aim of this research is to design and optimise a novel detection 
system to analyse five markers that have been shown to be linked to neural tube 
defects. The developed detection system consists of three steps: an initial multiplex 
PCR, a hemi-nested multiplex PCR, and a multiplex SNE-PCR using the ABI Prism® 
SNaPshot™ kit. The additional step of a hemi-nested PCR has been incorporated to 
increase the sensitivity and specificity of the test. By detecting all five markers 
simultaneously, the linkage between each of the mutations can be ascertained more 
rapidly than if detected independently. Four different sample types were analysed, 
modern DNA, experimentally degraded DNA, medical specimens and archeological 
samples. The genotypes were successfully generated for all the samples except the 
archeological samples, where only partial genotypes were achieved. The designed 
detection system can be applied to archive medical specimens (biopsies, smears, and 
blood donor cards), archeological material, and other degraded samples. Future 
applications of this technique can include medical screening, population mapping, 
association studies, familial pedigrees, and the study of the evolution of diseases. This 
developed three step methodology can be applied to the detection of other diseases 
and conditions. 
1 Introduction 
The term 'genome' was first introduced by Hans Winkler (1920), a botanist at the 
University of Hamburg in Germany, by combining the sounds and meanings of the two 
words GENe and chromosOME. The genome of an organism is its entire hereditary 
information encoded as DNA and includes both coding and non-coding sequences or, 
for some viruses, it's RNA. In eukaryotes the genome is organised into chromosomes, 
the first genetic map of a Drosophila melanogaster chromosome was accomplished by 
the American geneticist Alfred Sturtevant (1913) based on his observations of linkage 
analysis. The most influential breakthrough for genome research was the discovery of 
the double helical structure of the DNA molecule in 1953 by Francis Crick and James 
Watson (Watson and Crick 1953a; Watson and Crick 1953b ). DNA is an anti-parallel 
double stranded helical macromolecule in which the backbone consists of alternating 
sugar and phosphate groups joined by nitrogenous bases. The genetic code or DNA is 
made up of four nitrogenous bases: Adenine (A), Cytosine (C), Guanine (G), and 
Thymine (T). Each base from one strand binds to a base on the other strand; this is 
called complementary base pairing. In order to maintain a balance between the two 
complementary strands, a purine must bond with a pyrimidine via hydrogen bonds. Two 
hydrogen bonds form between A and T, while three hydrogen bonds are present 
between the C and G. In 1975, Frederick Sanger developed the chain termination 
technique to sequence DNA, also known as the dideoxy-termination method or the 
Sanger method (Sanger eta/. 1977b). Two years later, Sanger eta/. (1977a) 
successfully completed the sHquencing of the 5368bp genome of the phage ¢-X174, 
the first genome to be sequenced. In 1976, Walter Fiers completed the sequence of the 
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first RNA based genome of the bacteriophage MS2 (Fiers 1976). The polymerase chain 
reaction (PCR) was developed by Kary Mullis which allows the amplification of specific 
regions of DNA and has fuelled the development of modern molecular techniques 
(Mullis eta/., 1986). AutomatHd sequencing followed along with the possibility of 
analysing the entire human gE!nome. The human genome consists of 23 pairs of 
chromosomes, with each parBnt contributing one chromosome to each pair. The entire 
genome of eukaryotes typically includes the nuclear and the mitochondrial genomes. 
The human mitochondrial genome was sequenced in 1981 (Anderson 1981). The $3-
billion dollar 'Human Genome Project' (HGP) began in 1990, to map and sequence the 
human genome. It was estimated to take 15 years to complete (U.S. Dept. of Health 
and Human Services 1990). However, widespread international effort and cooperation 
comprising geneticists from Clhina, France, Germany, Japan, and the United Kingdom 
greatly aided the project's progress. As well as rapid technological advances in the field 
of genomics such as: (1) the use of restriction fragment-length polymorph isms; (2) the 
polymerase chain reaction; (3) developments in sequence analysis; (4) development of 
bacterial and yeast artificial chromosomes, which are now preferred in sequencing 
procedures because of their superior stability and larger size. These technological 
advances accelerated the completion of HGP producing a 'rough or working draft' of the 
human genome in November 2000 (November 2000; White House Press Release June 
26, 2000) and published in Nature (International Human Genome Mapping Consortium 
2001) and Science (Celera Genomics Sequencing Team 2001 ). These drafts 
represented 90% of the entire genome. The remaining 10% included the telomeres, 
and around the centromeres, where few if any genes are expected to be located. The 
12 
announcement of the completed genome in April 2003, coinciding with the 501h 
anniversary of the discovery of the DNA double helix, two years ahead of expectation 
and significantly under original spending projection (Henry 2003). All three billion base 
pairs in the human genome were sequenced creating a "blueprint" that contains all the 
information required for the construction, assembly, and operation of the human body. 
The HGP has lead to the fields of genomics and proteomics where over 20,000 
genes have been identified and their biological functions are being determined 
(International Human Genome Sequencing Consortium 2004). The project has become 
a landmark to an ever expanding field of genomics leading to the consideration of 
genomic sequencing of other organisms, such as commercially important species (i.e. 
crop plants and livestock) (Honeybee Genome Sequencing Consortium 2006; lhara et 
a/. 2004; International Rice Genome Sequencing Project 2005) species that have a 
relevance to human health (i.e. pathogenic bacteria or vectors of diseases) (Gardner et 
a/. 2002; Holt eta!. 2002; Parkhill eta/. 2003; Shimizu eta/. 2002; Waterston eta/. 
2002), and species that could help answer evolutionary questions (i.e. chimpanzee) 
(Cheng eta/. 2005; Chimpanzee Sequencing and Analysis Consortium 2005; Hughes et 
a!. 2005; Khaitovich eta!. 2005). The HGP has lead to numerous related projects such 
as: the SNP Consortium; the NIH Cancer Genome Project; HapMap; and the Human 
Genome Diversity project. 
The genomic era has created a revolution in biology by seeking to correlate 
genetic variations with phenotypic differences. In humans, these traits range from hair 
colour, eye colour, skin colour, and blood group, to disease susceptibility. Some 
variations in the DNA sequence do not produce a detectable change in biological 
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function while others do with e~ither positive or negative consequences. The positive 
effects can include a mutational change that causes an increased resistance to an 
infection or disease, such as the Ll32 deletion of the chemokine (C-C motif) receptor 5 
(CCR5) gene. Homozygotes for the allele exhibit a strong, although incomplete, 
resistance to HIV infection, whereas heterozygotes display delayed progression to 
acquired immunodeficiency syndrome (AIDS) (Bianpain eta/. 2002). Negative 
consequences include diseases, syndromes or conditions and there are many human 
diseases that have. a genetic cause. Some diseases have a large genetic component 
such as Huntington's disease, Tay-Sachs disease, or cystic fibrosis, while cancer, 
diabetes and heart disease possess a more modest genetic component because 
humans inherit only a predisposition and not a certainty of developing the disease. 
Genetic disorders can be grouped into three categories: single gene disorders, 
chromosome disorders, and multifactorial inheritance disorders. Single gene disorders 
are the product of a single gene mutation that can be present on one or both 
chromosomes. They may be autosomal or X-linked and are usually found as recessive, 
dominant or co-dominant. Examples of single gene disorders are Duchenne's muscular 
dystrophy and Huntington's disease (Emery 2003; Gusella and Macdonald 2006). 
Chromosome disorders are caused by an excess or deficiency of the genes located on 
chromosomes or structural changes within the chromosomes. An extra copy of 
chromosome 21, with no abnormal individual gene, causes Down's syndrome (Capone 
2001 ). Multifactorial inheritance disorders or polygenic diseases are caused by the 
interaction of a number of genes in conjunction with the environment. Heart disease, 
most cancers, obesity and alcoholism are examples of these multifactorial disorders. 
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Some diseases, even when they cause morbidity and mortality can be kept in the 
population by selective pressures. An example is sickle hemoglobin (Hbs) causing 
sickle cell anaemia in which the heterozygous state provides a selective advantage in 
environments affected by malaria (Aidoo eta/. 2002; Williams et at. 2005). Likewise, 
cystic fibrosis can confer resistance to cholera (Bijman eta/. 1 988; Rodman and 
Zamudio 1991 ). In the right environment, the incidence of these diseases can remain 
quite high, while elsewhere in the world where there are no selective pressures the 
incidence drops. 
The complete human genome has motivated research on understanding complex 
genetic diseases, disorders, and conditions. In order to associate specific genetic 
variations with conditions, genome-wide association studies are necessary. 
Researchers compare the genomes of affected and unaffected (control) individuals, and 
identify specific regions that differ between the two groups. The genetic differences 
can identify individuals with an increased risk for developing the condition which can 
then be exacerbated by environmental triggers. Genes associated with Duchenne's 
muscular dystrophy (Koenig eta!. 1 987), retinoblastoma (Dryja eta/. 1 986; Lee eta!. 
1 987), and cystic fibrosis (Kemm eta/. 1 989; Riordan eta/. 1 989; Rom mens eta/. 1 989) 
were the first to be mapped and cloned. Recently, researchers have announced the 
discovery of new genes associated with breast and ovarian cancer (Hughes-Davies et 
a/. 2003); type-2 diabetes (Gunton eta/. 2005); and Alzheimer's disease (Rogaeva eta/. 
2007). 
There are many benefits of studying human genetic variations and their 
phenotypic manifestations. Thle ability to associate certain mutations and genes with 
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specific conditions can shed light on the causes and factors of these diseases. Such 
knowledge can lead to the development of new therapies and strategies to treat or even 
prevent these diseases. By recognising the genotypic differences and their implications 
towards treatments, researchers can determine how individuals may respond to 
treatments based on their genotype and which strategies are more effective for their 
recovery. Understanding of such correlations can result in a new generation of 
medicines that target diseases with increased precision and reduced risks, a developing 
field that is known as pharmacogenomics. Expanding our biochemical knowledge of 
disease-related genes will lead to the development of innovative drugs that target 
theses specific biological functions. 
1. 1 Genetic Mutations 
A mutation can be defined as any heritable change in the sequence of 
nucleotides in DNA that causels a permanent alteration of genetic information (Horton 
2002). Mutations contribute to phenotypic variation and influence an individual's 
anthropometric characteristics, risk of disease and response to the environment 
(International SNP Map Working Group eta/. 2001 ). A mutation can involve insertions, 
deletions or substitutions of one or more bases in the DNA molecule. 
Deletions and insertions range from changes of a single nucleotide to ones that 
involve a genetic region. A frameshift mutation, where one to three bases are added or 
removed from the DNA molecule, causes a shift in the codon reading frame (Tamarin 
1991 ). These are potentially the most devastating in their effects on an organism 
because the sequence of a gelne changes from the site of mutation onward. Deletions 
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and insertions can also cause large-scale changes in the amino acid composition of the 
polypeptide chain and can lead to non-functional genes (Cummings 1994 ). 
A nucleotide substitution, also referred to as a single nucleotide polymorphism 
(SNP) (International SNP Map Working Group eta/.), does not modify the number of 
nucleotides but entails a variation within the sequence in which a single nucleotide is 
exchanged for another. The rnost common form of sequence variation, nucleotide 
substitutions consist of three types of mutations: a missense mutation, a nonsense 
mutation and a sense mutation (Cummings 1994 ). A missense mutation is a single 
nucleotide change that results in the substitution of one amino acid for another in a 
protein. A nonsense mutation changes an amino acid-specifying codon to one of the 
three terminating codons; resulting in a shorter polypeptide chains due to the premature 
termination of translation. A sense mutation produces elongated proteins since a 
terminating codon has been changed into one that codes for an amino acid. Nucleotide 
substitutions may affect gene functionality, gene presence, alter the morphology or 
physiology of the organism resulting in phenotypic consequences, or have no noticeable 
phenotypic effects. 
1.1.1 Single Nucleotide Polymorphisms 
A single nucleotide polymorphism (SNP) is usually a bi-allelic nucleotide 
substitution that exists in normal individuals in some populations. A true SNP 
designation requires the allele to be present at or above 1% frequency in the tested 
population (Brookes 1999). Human genomes are 99.9% identical and of the 0.1% 
difference, 90% are SNPs (Collins eta/. 1998; Li and Sadler 1991; Wang eta/. 1998). 
Phenotypic differences can be attributed to SNPs; and this is the basis for genetic 
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diversity found among humans. Single nucleotide polymorph isms occur on average 
every 1 ,000 bases when any two chromosomes are compared making them more 
prevalent in the genome than microsatellites (Cargill eta/. 1999; Kwok eta/. 1996; Li 
and Sadler 1991; Wang eta/. 1998). Currently, more than 1.4 million SNPs have been 
identified in the human genome (International SNP Map Working Group eta/. 2001 ). 
There are two types of SNPs: transitions (C~ T or G~A) and transversions (C~A, 
c~G, T ~A and G~ T). Approximately two thirds of SNPs involve transitions (Brookes 
1999). There are three possible genotypes when a SNP occurs; in the case of a C-G 
mutation, there could be a CC, CG and GG genotype. The nomenclature for this bi-
allelic system is CC when both alleles have a cytosine in that SNP position. 
Alternatively, a CG represents a heterozygote where one allele has a cytosine and the 
other allele has a guanine. 
Their extreme abundance in the genome indicates that SNPs can occur in both 
coding and non-coding regions (Syvanen 2001 ). This allows linkage between SNP 
variations within gene sequences and observed changes in gene function. 
Consequences at the phenotypic level depend on the location of the SNP. The SNPs 
located in non-coding regions have no direct known impact on the phenotype of an 
individual and can serve as biomarkers. Whereas, SNPs found in coding regions that 
alter the function or structure of the encoded proteins are a necessary and sufficient 
cause of most of the known inherited monogenic diseases (Syvanen 2001 ). These 
SNPs are important for diagnostic purposes. 
SNPs are also considered to be very stable heritable markers with relatively low 
mutation rates in comparison with other types of genetic markers (Carlson eta/. 2001) 
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and seem to mutate randomly (Crow 1995; Li eta/. 1996a). These characteristics 
render SNPs a valuable tool for a broad range of disciplines. The analysis and 
identification of multiple SNPs can generate a SNP profile. This SNP profile can be 
applied for identification purposes in forensic criminal profiling for differentiating 
between individuals, populations and ethnic groups (Chakraborty eta/. 1999; Collins et 
a/. 1997; Risch and Merikangas 1996). The stability of SNPs allows a SNP profile to be 
used in the study of human history and evolution (Hacia eta/. 1999; International SNP 
Map Working Group eta/. 2001; Jorde eta/. 2000). A generated SNP profile can be 
used in conjunction with mitochondrial DNA haplotyping (Nelson eta/. 2007) to follow 
inheritance patterns in humans over time or to identify inheritance patterns of 
chromosomal regions from generation to generation (Mountain eta/. 1992). Single 
nucleotide polymorphisms are also of interest in the field of pharmacogenomics for 
predicting individual variations in drug response and identifying new targets for drug 
design (Paste 2001 ). The specificity and sensitivity of SNPs enables the study of 
archeological specimens that can provide insight into the evolution of diseases such as 
the analysis of cytokines by Turner eta/. (2002). 
The study of SNPs is important because they contribute to our understanding of 
the underlining genetic causes of diseases and conditions that manifest in the clinical 
phenotypes. Researchers have shown that many clinical phenotypes have a 
considerable genetic componHnt like SNPs (Brookes 1999). Some SNPs located in 
genes can be expected to dirE!Ctly affect protein structure or expression levels, and 
these may represent candidate alterations for genetic mechanisms in disease 
(Landegren eta/. 1998). Attempts to correlate individual and combination of SNPs with 
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phenotypes that act either as markers and/or are causative for common multifactorial 
disorders such as cancer, cardiovascular disease, mental illness, auto-immune states, 
and diabetes, who are expected to be heavily influenced by the individual's SNP 
patterns in certain key susceptibility genes (Brookes 1999). However, the effect of 
genotype on disease phenotype does vary between disorders and populations owing to 
genetic and environmental heterogeneity (Weiss and Terwilliger 2000). It is the 
combined effect of a collection of SNP alleles in sets of key genes, plus environmental 
factors, that together determine whether an individual suffers from a particular disease 
(Brookes 1999). Eventhough SNPs contribute to conditions and diseases have 
environmental factors and the study of SNPs requires extensive research. 
SNPs can therefore be used to identify genetic components and factors 
associated with complex diseases and identify individuals who are predisposed and at 
risk (Chakraborty eta/. 1999; Collins eta/. 1997; Johnson and Todd 2000; Risch and 
Merikangas 1996). If a SNP contributes an increased risk for disease occurrence, that 
polymorphism should therefore be found at a higher frequency in individuals with that 
disease compared to non-disease controls, associated with the phenotype (Brookes 
1999). Assays that could analyse all the SNPs in large sets of patients and matched 
non-disease controls for all the complex phenotypes should be developed (Brookes 
1999). 
After the completion of the HGP, a SNP revolution began in which SNPs were 
the focus of much attention as a race to identify and associate SNPs motivated rapid 
technological progress. The unique characteristics of SNPs allow them to be amenable 
to automated, large-scale, high-throughput genotype analysis. This has been the 
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driving force to develop new methods and techniques in the quest to better understand 
complex diseases which will have a tremendous impact on human biology. 
1.2 Birth Defects 
A birth defect, or congenital malformation, is defined as an abnormality of 
structure, function or metabolism present at birth that results in physical or mental 
disabilities or death (March of Dimes 2007). Birth defects are the result of an 
abnormality during the developmental process and can occur in any major organ or part 
of the body. Most birth defects occur during the first three months of pregnancy and 
their severity ranges from mild implications to serious complications. Some birth 
defects can be life threatening, lead to lifelong disability and require costly medical care 
and multiple hospitalisations. Some can be diagnosed through prenatal screening (e.g. 
Down syndrome), at birth (e.g. achondroplasia), within the first few years of childhood 
(e.g. phenylketonuria), or anytime later in life (e.g. Huntington's disease). 
Approximately 3% of babies are born with birth defects (Centers for Disease 
Control and Prevention (CDC) 2006; Greenberg 1991; Moore 1988b). By the end of the 
first year, detection of malformations that were not obvious at birth increases to 6% 
(Moore 1988b ). Birth defects are the leading cause of death in the first year of life in the 
developed world (Martin et at. 2005; Pinar 2004 ). Birth defects can occur as an isolated 
abnormality or in association with or combined with other abnormalities (Greenberg 
1991 ). When multiple defects occur together and have a similar cause, they are called 
syndromes (Greenberg 1991 ). If two or more defects appear together but do not share 
the same cause, they are called associations (Greenberg 1991 ). Known causes of birth 
defects include single gene disorders, chromosome abnormalities and environmental 
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exposures such as infectious diseases or harmful chemical agents during pregnancy 
(Mitchell 2005). Birth defects can be grouped into four categories: structural and 
metabolic abnormalities; congt3nital infections; and other conditions (Copp 1994; March 
of Dimes 2007; Stevenson 1993). 
Structural birth defects are the result of abnormal development in which an 
internal or external body part is missing or has formed incorrectly. Examples of a 
structural defect would be a cleft lip and a cleft palate (Mitchell 1997). Metabolic defects 
are caused by a biochemical disruption from missing or incorrectly formed enzymes 
which facilitate the conversion of various substrates into other products. An imbalance 
will create either a deficiency, or an accumulation of substrates. A deficiency may 
reduce the ability to synthesist3 essential compounds while substrate accumulation can 
be toxic or interfere with normal function (Cummings 1994 ). Gaucher's disease is an 
example of a metabolic birth defect (Brady 2006). This disease causes an abnormal 
build-up of a fatty substance called glucocerebroside throughout the body that becomes 
toxic to organs and tissues, resulting in progressive and permanent damage (Beutler 
1995). 
Birth defects resulting from congenital infections appear when a mother acquires 
an infection prior to or during pregnancy and it can cause deafness, blindness, mental 
retardation, or heart defects. Cytomegalovirus and rubella are common congenital 
infections (Moore 1988b ). Other conditions that cause birth defects are fetal alcohol 
syndrome, illicit drug use, and Rhesus disease. To date, several thousand different 
birth defects have been identified, however, the causes of 70% of birth defects are still 
unknown (Centers for DiseasE:! Control and Prevention (CDC) 2006). 
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1.3 Neural Tube Defects 
Neural tube defects (NTDs) are an important category of birth defects. These 
congenital malformations of the central nervous system (CNS) are the second most 
common birth defects, the first being congenital cardiovascular abnormalities (Manning 
and Archer 2001 ). Congenital defects of the CNS arise from complex embryological 
malformations related to the growth and development of the brain, skull and spinal cord. 
Defects may include all congenital abnormalities which involve the failure of the neural 
tube to properly close during the fourth week of human embryogenesis, with defects 
occurring at any point along the formation of the spinal cord, either rostrally from the 
developing brain and caudally to the sacrum (Finnell eta/. 2003). Their severity 
depends on the size, level or location of the defect along the neuroaxis of the embryo 
and whether the defect crosses CNS segmental boundaries. 
Many NTDs often results in exposure of neural tissue to the environment. All 
NTDs appear to be etiologically heterogeneous (Holmes eta/., 1976) and multifactorial 
in origin; their cause is attributed to a combination of genetic and environmental factors. 
The most important environmental factors include geography, month of conception, 
epidemic trends, maternal age, birth order, socio-economic class, maternal diet, 
maternal diabetes, maternal obesity, and maternal illness and drug exposure (Elwood 
1992). 
A genetic predisposition for NTDs has been supported by several lines of 
evidence. The incidence of f\ITDs varies greatly among populations and ethnic groups, 
suggesting that there are genetic factors that may explain the differences in prevalence 
(Copp and Bernfield 1994 ). There is a significantly higher prevalence of consanguinity 
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among parents of infants with NTDs, suggesting a clustering of affecting genes within 
families that may possibly contribute to NTD in some way (Elwood 1992). The risk of 
occurrence of NTDs in offspring of parents with prior affected pregnancies is 
substantially higher not only for those parents but also for their first-, second-, and third-
degree relatives. The risk for NTDs is highest among first-degree relatives and 
decreases for more distant relatives. The risk of occurrence for siblings of an affected 
individual is 2-5%, representing a 25-50 fold increase compared to the general 
population (Elwood 1992). The increased risk also appears to extend to cousins of the 
affected individual, although possibly to only maternal cousins (Carter 1974). The risk 
of reoccurrence, for women who have had one affected infant, is increased by at least 
1-3% above that of the general population (Papp eta/. 1997; Pietrzyk 1983; Swerts et 
a/. 1987; Thunem eta/. 1988) .. In addition, females and monozygotic twins appear to be 
more prone to NTD (Hall1998). Neumann eta/. (1994) interpreted such data to argue 
that human NTDs exhibit approximately 60% heritability. These observations support a 
prominent role for genetically inherited components in the occurrence of NTDs. 
The term neural tube defect encompasses a broad range of malformations, 
rendering this condition difficult to classify. The spectrum includes: anencephaly; spina 
bifid a; encephalocele; iniencephaly and craniorachischisis (Figure 1) (Hall 1998). 
Classification of NTDs varies among the medical literature. NTDs can be grouped as 
"open" where the brain and/or spinal cord are exposed at birth through a defect in the 
skull or vertebrae, or "closed" where the spinal defect is covered by skin (Elwood 1992; 
Mitchell 2005). They can also be typed as NTDs that affect cranial or spinal structures 
(Frey and Hauser 2003). Another way of classifying NTDs is based on its position 
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along the length of the neural tube, whether it is high or low (Blatter eta/. 1997). This 
classification is similar to that of the cranial/spinal grouping. Newer classification 
schemes attempt to divide these malformations by their locations rather than by gross 
anatomical characteristics. 
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Figure 1 -Types of Neural Tube Defects 
1.3.1 Anencephaly 
The two most common types of NTDs observed in humans are anencephaly and 
spina bifida cystica (Detrait eta/. 2005; Hall 1998). Anencephaly was first described by 
von Recklinghausen in 1886 in which he suggested that the birth defect is caused by 
improper closure of the neural tube (von Recklinghausen 1886). Anencephaly 
comprises 50-65% of all NTDs and is immediately noticeable at birth (Hunter 1993; 
Thomas eta/. 1994 ). This condition is lethal; most infants are stillborn or die shortly 
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after birth, usually within 48 hours (Elwood 1992; Hunter 1993). This type of 
malformation results from incomplete closure of the cephalic portion of the neural tube 
leading to partial (meroanencephaly) or complete absence (holoanencephaly) of the 
cranial vault (skull), overlying tissues and cerebral hemispheres as well as an abnormal 
development of the skull base. The remaining degenerated brain tissue that consists of 
a small, spongy, vascular mass of disorganised neural tissue is referred to as the 'area 
cerebrovasculosa' (Elwood 1992). Holoanencephaly accounts for 65% of anencephaly 
cases and is characterised by a defect that extends through the foramen magnum 
(Myrianthopoulos and Melnick 1987). Meroanencephaly is a milder defect in which the 
area cerebrovasculosa protrudes through a partially formed skull (Myrianthopoulos and 
Melnick 1987). In both types, the eyes are bulging, giving a frog-like appearance and 
the neck is usually short (Figure 2) (EI-Ghani 2006). The brain stem is present but is 
usually incomplete; the infant's face has the characteristic appearance of an elevated 
and pointed nose (Elwood 1992). 
Figure 2- Infant affected with anencephaly (Cohen 2002) 
1.3.2 Craniorachischisis 
Craniorachischisis, sometimes considered a subtype of anencephaly, is a rare 
and severe condition in which the neural folds never elevate to fuse along the entire 
26 
length of the embryo causing incomplete closure of the skull and spinal column (Finnell 
eta/. 2003). This type of malformation is characterised as anencephaly with continuous 
involvement of the spine and no meninges covering the neural tissue. Like 
anencephaly, this condition is lethal (Hall 1998) and 80% of holoanencephaly cases are 
associated with craniorachischisis (Melnick and Myrianthopoulos 1987). The defect can 
be limited to the cervical region or the entire spine resulting in the CNS being exposed 
to the surrounding amniotic fluid, thus causing necrosis, degeneration or angioma-like 
formations. The condition is sometimes associated with severe anterior flexion of the 
spine, causing the infant to gaze upward (Figure 3) (Hunter 1993). 
I I 
Figure 3- Child affected with craniorachischisis (Moore eta/. 1997) 
1.3.3 lniencephaly 
lniencephaly is a very rare NTD that combines extreme retroflexion of the head 
with severe distortion of the spine. Affected newborns do not generally live more than a 
few hours. The disorder is more common among females by a ratio of 10:1 (Hunter 
1993). lniencephaly is characterised by a defect in the occipital region accompanied by 
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cervical and thoracic vertebrae that are partially or completely absent, with the 
remaining vertebrae irregularly fused and with defective closure of the vertebral arches. 
This malformation results in fusion of the cranial area to the caudal area, causing 
continuity of the skin of the face to the chest and the skin of the scalp to the back. This 
condition is similar to craniorachischisis with its retroflexion of the spine; however, in the 
latter the cervical and thoracic vertebrae remain identifiable. Most infants tend to be 
short with a disproportionately large head and an absent neck (Figure 4 ). Individuals 
with iniencephaly usually havH other associated anomalies such as anencephaly and/or 
a meningomyelocele present (Hunter 1993). 
Figure 4- Newborns with iniencephaly (Moore eta/. 1997) 
1.3.4 Encephalocele 
Encephalocele is apparent upon examination of the newborn and is relatively 
less common than spina bifida and anencephaly (Hunter 1993). This birth defect is 
thought to be due to the failure of closure of the anterior neural tube at a slightly later 
stage of embryogenesis than in anencephaly. This condition is characterised by the 
incomplete development of the skull which results in a saccular herniation that extends 
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through the midline defect in the calvaria (Figure 5). Pressure within the skull 
subsequently pushes cranial tissue out through the opening (EI-Ghani 2006). The 
contents of the sac may contain one or all of the following intracranial contents: the 
protective membranes normally covering the brain known as the meninges; 
Figure 5 -Child with encephalocele (Cohen 2002) 
cerebrospinal fluid (CSF); and/or some brain tissue. Herniation of the meninges 
through the cranial defect is termed 'cranial meningocele', whereas herniation of brain 
tissue, meninges and CSF through the bony defect is called an 'encephalocele' (EI-
Ghani 2006). The meninges can grow to cover the protrusion as skin does in some 
cases. The severity of the protrusion can vary in size; varying from very small to larger 
than the head of the infant. In either case, the sac must be excised so that the skin 
does not erode and cause mEmingitis. Encephalocele can be classified as occipital, 
anterior or parietal (Cohen 2002); the frequencies being about 75%, 10% and 15% 
respectively within the US population (Lemire 1988). The herniated sac can also be 
covered with either normal skin or a thin epithelium (Campbell eta/. 1986). The 
neurological impairment depends on the extent of brain involvement; there can be little 
to no brain tissue or the protrusion may contain a significant fraction of the brain 
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resulting in severe brain damage. Thus, the greater the neural abnormalities, the 
greater the rate of mental retardation (Bozinov eta/. 2005). 
1.3.5 Spina Bifida 
Spina bifida (SB), also known as spinal dysraphism, means 'split spine' in Latin 
and can be referred to as 'open spine' (Freeman 1980). This term is used to describe 
many varieties of lesions due Io midline separation of the vertebrae (Elwood 1992). It is 
a posterior NTD characterised by caudal lesions affecting the spinal cord, vertebrae and 
skin (Botto eta/. 1999). This birth defect presents at birth with a lesion on the back 
(Freeman 1980). SB varies in severity, ranging from asymptomatic to clinically 
significant types. This condition results from failure of the halves of the vertebral arch of 
one or more vertebrae to develop normally and fuse in the median plane (Moore 1988). 
Lesions can occur at any location along the spine and vary in size from a single 
vertebra to the entire neuroaxis (Hunter 1993). SB is subdivided into three main 
classes: spina bifida occulta (SBO), spina bifida cystic or aperta and myeloschisis. 
SBO, often called 'hidden' spina bifida, is the mildest form of spina bifida in which 
disability is rarely seen (Northrup and Volcik 2000). This malformation usually affects 
only one or two vertebrae. The split in the vertebrae is so small that the spinal cord and 
the meninges are in their normal position within the vertebral canal and are usually not 
involved or herniated. Thus there is no opening in the back or sac protruding and the 
defect is completely covered by skin (Figure 6). Spina bifida occulta occurs mostly in 
the lumbosacral region of the spine in the L5, 81 and/or 82 vertebrae in about 10-25% 
of healthy individuals and is regarded as a normal variation in the population (Botto et 
a/. 1999; Moore 1988b; SBHAC 2000). In many cases, it is neurologically 
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asymptomatic and is often diagnosed incidentally during a radiographic exam of the 
lower spine (EI-Ghani 2006). However, if several vertebrae are affected bowel, bladder 
and motor problems, weakness and numbness of lower limbs, as well as foot 
deformities may arise (SBHAC 2000). 
Figure 6- Spina Bifida Occulta (Botto eta/. 1999) 
Approximately 80% of individuals with spinal cord malformations exhibit some 
type of skin abnormality overlying the defect which can also be indicative of the 
condition (Kinsman 2001; van der Put eta/. 2001 ). These skin defects include: a hairy 
patch; fatty lump (lipoma); hemangioma; dark spots or birthmarks; skin tract or sinus 
(i.e. a deep dimple); and hypopigmented spots (Figure 7) (Kinsman 2001 ). 
Spina bifida cystica or aperta is a severe open neural tube defect because it 
involves the protrusion of a herniated sac containing meninges or meninges and spinal 
cord tissue through a defect in the vertebral arches (Northrup and Volcik 2000). It is 
termed cystica because of the cyst-like sac that is associated with this type of 
malformation. Individuals affected can survive into adulthood with considerable disability 
depending on the severity, type and location of the lesion. Spina bifida cystica has two 
subclasses: myelomeningocele or meningomyelocele and meningocele. Although this 
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condition can occur at any level, it most commonly occurs in the lumbar or lumbosacral 
regions of the spine (Moore 1988b ). 
Figure 7- Examples of skin abnormalities associated with Spina Bifida such as a dimple (Moore 
1988b); a tuft of hair and lipoma (!Pierre-Kahn eta/. 1997) 
In about 10% of SB cases the malformation consists of a dorsal protrusion of a 
fluid-distended sac through the incompletely formed vertebrae. This meningocele 
contains only meninges and CSF (Hunter 1993). The spinal cord and spinal roots are in 
their normal position and the sac is usually, but not always, covered by normal skin 
(Figure 8) (Northrup and Volcik 2000). The defect can be surgically repaired with little 
nerve damage. 
Figure 8- Spina bifida meningocele (Botto eta/. 1999) 
About 90% of SB cases in neonates are myelomeningoceles (Hunter 1993). This 
condition is characterised by saccular herniation containing the spinal cord and/or nerve 
32 
roots, CSF and the meninges through a large vertebral defect of the spine (Figure 9) 
(Botto et at. 1999). The lesion may be covered by a thin layer of skin or a transparent 
membrane (Kaplan eta/. 200S). The top of the protruding sac is often a soft, fragile, 
"area medullavasculosa" consisting of blood vessels, pia mater and neural remnants 
(Hunter 1993). 
Figure 9- Spina bifida myelomeningocele (Botto eta/. 1999) 
Meningomyelocele is more severe than meningocele because the condition 
results in a marked neurological deficit inferior to the level of the protruding sac 
(Northrup and Volcik 2000). SB myelomeningocele demonstrates variable degrees of 
neurological impairment based on three factors: location of lesion; extent of lesion; and 
interruption of the spinal cord or spinal cord and tissue involvement. In fact, 99% of 
children born with an open NTD have some type of handicap which can include: motor 
and sensory dysfunction or paralysis of lower limbs; anaesthesia of the skin; poor or 
nearly absent bladder and bowel control, and abnormalities of hips, knees, or feet (e.g. 
club foot and rocker bottom foot) (EI-Ghani 2006; Northrup and Volcik 2000; 
Padmanabhan 2006). Other complications commonly seen are severe forms of 
scoliosis, kyphosis or lordosis as well as meningitis, tethered cord syndrome and 
33 
diastematomyelia (Kaplan eta/. 2005). Patients with more severe forms of SB have 
Arnold-Chiari type II malformation of the cerebellum which is believed to be a secondary 
effect of hydrocephalus (Lemire 1 988). Hydrocephalus is the accumulation of CSF in 
the ventricles of the brain and/or between the brain and dura mater (Moore 1988). As a 
result of the NTD, the CSF is unable to drain normally causing the head to become 
enlarged. All individuals with thoracic SB and most of the patients with lumbosacral SB 
are at increased risk for hydrocephalus and Arnold Chiari type II malformation (Melone 
and Dias 2003; Rintoul eta/. 2002). Hydrocephalus is associated with 90% of 
lumbosacral SB; cervical, thoracic, and sacral lesions are less often complicated with 
hydrocephalus (Figure 1 0) (Hunter 1 993; Lemire 1 988). 
Figure 10- Thoracic and lumbar myelomeningocele (Moore 1988b); lumbar myelomeningocele 
(Davies and Duran 2003). 
The third and most severe type of SB is called myeloschisis. This defect occurs 
when the developed spinal cord is exposed to the external environment, because the 
dermal or meningeal covering is absent. There is no cystic sac observed in this 
condition and hair is usually found growing around the defect. CSF leaches from the 
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opening of the affected area and the spinal cord is represented as a raw, red, flattened 
mass of nervous tissue (Figure 11) (Moore 1988b ). This causes paralysis of the lower 
limbs and pelvic organs (Moore 1988). Like meningomyelocele, there are the same 
associated complications and chance for severe infection and if not corrected can cause 
death (Kaplan eta/. 2005). 
Figure 11 -Cases of myeloschisis (Akiyama eta/. 2006; Moore 1988b) 
1.4 Screening for Neural Tube Defects 
Screening programs aid in identifying pregnant women with increased risks for 
various conditions. Screenin£1 can lead to four possible outcomes: true positives which 
correctly identifies an individual as affected with the condition; false positives which 
incorrectly identifies an unaffected person as affected; true negative which correctly 
identifies an individual as unaffected and a false negative which incorrectly identifies an 
affected person as unaffected with the condition (Ormond 1997). Women who show 
positive results are offered a specific diagnostic test such as a targeted ultrasound 
examination, amniocentesis, or other obstetrical interventions. Today's screening 
techniques identify fetuses with chromosomal abnormalities (i.e. Down syndrome) and 
women at high risk for obstetrical complications during the third trimester (Rose and 
Mennuti 1993). The detection of maternal serum a-fetoprotein (MSAFP) is the earliest 
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non-invasive procedure that can be used during pregnancy to acquire information about 
the fetus (Rose and Mennuti 1 993). a-Fetoprotein (AFP) is the first embryonal serum 
protein that is produced durin~J the stages of fetal life (Muller 2003). It is filtered by the 
fetal kidneys and excreted through fetal urine into the amniotic fluid and then enters into 
maternal circulation by diffusion through the membranes or the placenta (Fuhrmann and 
Weitzel 1 985). Brock and Sutcliffe (1 972) first discovered that there was a significantly 
elevated amount of AFP in women carrying fetuses affected with open NTDs. The 
association between NTDs and increased AFP values in maternal blood has been 
shown in many studies (Brock eta/. 1 973; Brock eta/. 197 4; Harris eta/. 197 4; Seller et 
a/. 1974; Wald eta/. 1974). In the presence of an open NTD, large amounts of AFP is 
released into the amniotic fluid from the exposed lesion, causing an increased diffusion 
into the maternal serum (Fuhrmann and Weitzel 1 985). Studies have lead to routine 
laboratory testing for prenatal diagnosis of NTDs (Wald eta/. 1 977). 
MSAFP concentration peaks in the second trimester to a maximum at about 30 
weeks of gestation, and then declines until term (Drugan eta/. 2001; Seppala and 
Ruoslahti 1973). For screening in the UK (Wald eta/. 1977), a collaborative study 
determined that the optimal time for increased sensitivity to perform this test is between 
16 to 18 weeks gestation. During this period, the AFP levels are about four times 
greater in open NTD pregnancies than in unaffected pregnancies (Wald 1992). AFP 
levels can, however, be measured between 14 to 22 weeks of completed pregnancy but 
with lowered sensitivity (Ormond 1 997; Rose and Mennuti 1 993). As the fetus matures, 
AFP gradually decreases since albumin replaces AFP as the principal fetal plasma 
protein (Drugan eta/. 2001 ). Due to the variation of AFP concentrations, reference 
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ranges at each gestational age must be clearly determined prior to maternal serum or 
amniotic fluid testing (Muller 2003). Closed SB and encephaloceles are difficult to 
detect since MSAFP levels am often not elevated because the defect is skin covered 
causing AFP not to be released as much as an open NTD (Ormond 1997). 
Unaffected 
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Figure 12- Distribution curves of MSAFP in MoM at 16-18 weeks gestation among singleton 
unaffected and open Spina Bifida pregnancies (Wald 1992) 
A normal MSAFP result does not ensure an infant without abnormality nor does 
abnormal values conclusively indicate an abnormality present (Figure 12). Rather, 
elevated values indicate an increased risk that warrants further testing. False positives 
results may also be due to various factors such as: fetal demise, blood contamination, 
or serious malformations other than a NTD (Wald 1992). Abnormal MSAFP levels are 
not exclusively observed in NTDs, they can also be seen in several other congenital 
abnormalities such as abdominal wall defects (omphalocele and gastroschisis), skin 
defects like epidermolysis bullosa and aplasia cutis, congenital nephrosis, renal 
agenesis, sacroccycgeal teratoma, hemangioma, and bladder and cloacal exstrophy 
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(Drugan eta/. 2001; Harmon eta/. 1995; Nadel eta/. 1990). Abnormal MSAFP value 
can also be caused by other reasons such as: the presence of multiple gestations, 
incorrect assessment of fetal age, and pregnancies at high risk for poor outcomes. 
MSAFP levels in twin pregnancies are approximately double those observed in 
singleton pregnancies, and they are even higher for three or more fetuses (Wald eta/. 
1975). Elevated levels can be explained by the greater resorption area for 
transamniotic AFP transfer (Fuhrmann and Weitzel 1985). This may cause 
interpretation to be difficult resulting in false positive or false negative results (Johnson 
eta/. 1989). Underestimation of gestational age is the most common reason for an 
elevated maternal MSAFP (Rose and Mennuti 1993). Patients with inaccurate gestation 
times can result in either false positive or false negative results. Gestational age is 
usually verified during a subsequent ultrasound examination. 
Increased AFP levels may also indicate a higher risk for spontaneous abortion, 
impeding intra-uterine death (Fuhrmann and Weitzel 1985). Akinbiyi (1996) 
demonstrated that women with unexplained elevated MSAFP are at increased risk of 
pre-term labor, ante-partum hemorrhage and intra-uterine growth restriction. Early 
identification of these high risk patients warrants close monitoring and supervision of the 
pregnancy. Furthermore, other factors that affect the calculation of MSAFP levels and 
should be considered during the interpretation of results include: maternal ethnicity, 
maternal weight, and insulin-dependant diabetes. Women of Afro-Caribbean origin 
have AFP levels about 10-15% higher than other women but have a lower prevalence of 
NTDs (Crandall eta/. 1983; Cuckle 1994). This factor can cause a disproportionate 
number of women to have raised AFP levels. Women of Asian background have 
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MSAFP levels slightly elevated levels while Hispanic women have decreased MSAFP 
levels (Benn eta/. 1997; Crandall eta/. 1983). 
Maternal weight and MSAFP concentrations have been found to be inversely 
related (Crandall eta/. 1983). In larger women, increased plasma volumes can dilute 
the amount of AFP present and can lead to an underestimation of the AFP value. The 
reverse can be seen in smaller women (Ormond 1997; Wald 1992). This can lead to 
misidentifying a pregnancy as a high or low risk for NTDs (Adams eta/. 1984 ). Women 
with insulin-dependant diabetes are at an increased risk of having children with a NTD 
or other structural abnormalitiE!S (Milunsky 1982). MSAFP levels are reduced in 
diabetics by about 25% (Cuckle 1994; Wald eta/. 1979b). This could lead to erroneous 
'normal' values causing a decrease in the sensitivity of the test. 
When abnormal MSAFP levels are encountered it is the preliminary indication of 
the presence of an abnormality and the expecting parents are usually provided with 
genetic counselling in which the next steps are discussed (Figure 13). An ultrasound 
examination is usually performed to identify multiple gestations, intra-uterine death, and 
to verify gestational age. The observation of multiple gestations and fetal demise 
require further special prenatal care. Approximately 40% of elevated MSAFP cases are 
caused by incorrect gestational dating, with most being underestimated. Gestational 
age is determined by measuring from one outer edge of the fetal skull to the other in a 
transverse section. This is called the biparietal diameter (BPD) (Nicolaides eta/. 1986). 
Wald eta/. (1980) demonstrated that fetuses with SB had a mean BPD 16% lower than 
unaffected pregnancies at the same gestational ages. 
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Figure 13- Suggested Neural Tube Defect Determination Protocol. AFP- alpha-fetoprotein, AChE-
acetylcholinesterase, AFAFP- amniotic fluid alpha-fetoprotein, MoM- multiple of the median (Rose and 
Mennuti 1993 ). 
This factor would produce an apparently earlier gestational age thus making the 
MSAFP value appear even higher. The detection rate for open SB is then significantly 
increased to 90% or more (Wald eta/. 1980). If there is a discrepancy of more than one 
or two weeks in gestational a~le, the MSAFP is recalculated (Canick 1992). For women 
with normal MSAFP levels based on ultrasound dating, no further testing is 
recommended. As gestational age increases, MSAFP values tend to regress toward 
the mean of their group (Knight eta/. 1988). In NTD affected pregnancies, MSAFP 
levels would increase, however, unaffected pregnancies would result in decreased 
MSAFP levels (Ormond 1997). Those women who have their MSAFP test repeated, 
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30-40% of them would have a normal level on the second test, contributing to a lower 
risk for NTDs (Burton 1988). If levels are still elevated after a second test, the women 
are then offered a high resolution ultrasound examination to scan for anomalies. 
Detailed ultrasound examination is an alternative approach for the evaluation of 
the patients with high MSAFP levels. When combined with MSAFP screening, NTD 
detection rates are greatly improved. Anencephaly was the first type of NTD to be 
observed by ultrasound (Stephenson 2003). Today, anencephaly is virtually impossible 
to miss durin9 a sonographic examination and can be detected as early as 12-13 weeks 
(Aubry eta/. 2003). At 22 weeks of gestation, it is possible to diagnose NTDs such as 
encephalocele, SB meningocele, SB myelomeningocele, and sometimes SBO (Aubry et 
a/. 2003). Since SB can be missed by AFP screening and amniocentesis, sonography 
becomes a valuable tool in its identification (Wingate 2004 ). Sonography can visualise 
the cranial or spinal defect when the fetus is in a position with the amniotic fluid 
surrounding the protruding mass (i.e. Meningocele: Figure 14). Obvious disruption in 
the contour of fetal skin or bulging within the posterior contour of the fetal back are 
indicative of irregularities of the spine (Wingate 2004 ). 
Scanning the spine is also necessary to verify proper fusion of the vertebral 
arches which appear U-shaped if open. Spina bifida occulta can be extremely difficult 
to identify in the fetus since the defect is skin-covered and without a mass protruding. 
SBC, conversely, is more recognisable due to these protrusions. Brain and cranial 
abnormalities signify the possibility of a neural tube malformation, making it possible to 
detect NTDs so tiny that the IE3sion itself is barely noticeable or when the spine is difficult 
to visualise adequately. 
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Figure 14- Spina Bifida with meningocele image with a sac containing CSF and meninges 
protruding !through a sacral defect (Stephenson 2003). 
Nicolaides eta/. (1986) first described cranial anatomy alterations that were 
consistent features present in virtually all fetuses with SB, termed the lemon and 
banana signs (Figure 15). The lemon sign is due to temporal bone malformation and is 
represented by the 'scalloping', or pinching, of the frontal bones of the fetal skull 
producing a lemon shaped skull (Wald 1992). The lemon sign is indicative of an closed 
NTD more frequently than the banana sign (Nyberg eta/. 1988). The banana sign is 
caused by to the downward pulling of the cerebellum through the cisterna magna 
causing a distortion of the cenabellar hemispheres (Harmon eta/. 1995). The 
cerebellum exhibits an abnormal anterior curvature causing it to appear banana shaped 
which would normally look likEl a dumbbell (Wingate 2004 ). This feature is associated 
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Figure 15- Schematic representation (Left:(Nicolaides eta/. 1986)) a sonographic illustration 
(Right: (Ghi eta/. 2006)) of the banana and lemon signs in a fetus with SB. · 
is definitive evidence for the presence of a NTD in sonograms obtained before 24 
weeks gestation (Nicolaides eta/. 1986). Researchers have found that the lemon sign 
has a detection rate of 98% with a false positive rate of 0.8% for open SB; the rates for 
the banana sign are similar (Campbell eta/. 1987; Nicolaides eta/. 1986; Nyberg eta/. 
1988; Pilu eta!. 1988; Van den Hof eta/. 1990) . These markers will likely improve the 
diagnostic accuracy of ultrasonography in the evaluation of pregnancies at high risk for 
this fetal abnormality. Increasing resolution of sonography equipment and improved 
training of ultrasonographers will advance the sensitivity of ultrasound diagnosis. Van 
den Hof eta/. (1990) reported accuracies as high as 100% for the sonographic 
diagnosis of open spina bifida in 130 fetuses. Targeted sonographic evaluation of the 
fetus for NTD, is remarkably accurate with a sensitivity of 97%, specificity of 100%, and 
the positive and negative predictive values are close to 100% (Lennon and Gray 1999). 
It must be noted, however, that sensitivity is not the same for each anomaly (Nadel et 
a/. 1990). 
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Targeted ultrasound is sometimes performed in addition to or in place of 
amniocentesis (d'Ercole eta/. 2003; Kooper eta/. 2007; Nadel eta/. 1990). There is a 
debate as to whether it is necessary to perform amniocentesis as the procedure carries 
significant risk of adverse pregnancy outcomes with an estimated 0.5% fetal mortality 
rate (Kalata 1980; Taboret a/. 1986). Nadel eta/. (1990) suggest that a sonographic 
examination is a sufficient alternative to amniocentesis for the diagnosis of a NTD in 
patients with moderate elevations of the normal median (MoM) levels. AFP levels are 
expressed in multiples of the MoM established for each gestational week. Lennon and 
Gray (1999) believe that amniocentesis should be performed for the following situations: 
where the patient is at risk for a chromosomal disorder, an ultrasound finding suspicious 
for a chromosomal abnormality, greater than 3.0 MoM MSAFP results despite a normal 
scan, inability to properly visualise the fetal anatomy, or where the patient requests the 
procedure after adequate counselling. Samples of amniotic fluid can be assayed for 
amniotic fluid AFP (AFAFP), which will confirm the elevated MSAFP if a defect is 
present. Wald eta/. (1989) developed an effective and economical procedure to 
perform both types of biochemical testing. If MSAFP levels are elevated, but AFAFP 
values are normal with a normal ultrasound, an open NTD can be excluded with a high 
degree of confidence. These women are at high risk for obstetrical complications and 
should be monitored during their third trimester (Rose and Mennuti 1993). A secondary 
important diagnostic test, to evaluate acetylcholinesterase (AChE) (Collins eta/. 2003) 
levels, is performed concurrently with the AFAFP and enables the distinction between 
NTDs and other AFAFP related fetal defects (Kooper eta/. 2007). Elevated 
acetylcholinesterase levels, which leak into the amniotic fluid also indicates an open 
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neural tube defect (Kalata 1980). Acetylcholinesterase is an enzyme that is contained 
in blood cells, muscle and neural tissue (Rose and Mennuti 1993). When amniotic fluid 
AFP and AChE determinations are combined and both show elevated levels, it is 
indicative of open NTD, thus eliminating false positive results of the AFP tests (Brocket 
a/. 1985; Wald 1981 ). The combination of both measurements renders highly accurate 
diagnosis of open NTD via amniocentesis, with a 99% detection rate (Ormond 1997). 
Nevertheless, cytogeneltic evaluation could shed light on the genetic factors of 
NTDs and is recommended by some researchers (Babcook eta/. 1995; d'Ercole eta/. 
2003; Harmon eta/. 1995r Chromosomal abnormalities were diagnosed between 6.5-
17% karyotypes of fetuses with NTDs (Babcook eta/. 1995; Harmon eta/. 1995; 
Kennedy eta/. 1998; Sepulveda eta/. 2004 ). The need to further investigate this area 
justifies the risk of amniocentesis as it would affect the prognosis, intervention, 
outcome, and recurrence risks for future pregnancies. 
Early diagnosis decrease the morbidity and mortality rates by allowing 
preparation for the appropriate delivery strategies and post-delivery measures (Rose 
and Mennuti 1993). Cesarean section prior to labor has been reported to be more 
beneficial, for the infant who has greater neurological function, than those undergoing 
labor before cesarean section or vaginal delivery (Luthy eta/. 1991 ). Expectant parents 
are also provided with the necessary information early enough to make an informed 
decision as whether to terminate a pregnancy or not. The combination of all or most of 
these detection methods gives a clear indication of abnormality with a high degree of 
confidence. 
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1.5 Mutations of Interest 
1.5.1 Folic Acid and Homocysteine Metabolic pathway 
Folate deficiency has been associated with the occurrence and reoccurrence of 
selected birth defects, and studies have demonstrated that the risk of NTD to be 
dramatically reduced (by up to at least 75%) by preconceptional dietary folic acid 
supplementation (Czeizel and Dudas 1992; MRC Vitamin Study Research Group 1991 ). 
Folic acid is known to contribute to three metabolic pathways: remethylation, the folate 
cycle, and transsulfuration (Cabrera eta/. 2004). Although, the mechanism in which 
folic acid plays a protective role in preventing NTD is poorly understood, this suggests 
that folate-dependant enzymes may be functionally important in producing the disease 
phenotype. 
It has been shown that concentrations of homocysteine are mildly elevated in 
some pregnant women who subsequently give birth to NTD affected babies (Kruger et 
a/. 2000; Mills eta/. 1995; Steegers-Theunissen eta/. 1994; van der Put and Blom 
2000). Genetic alterations in cystathionine 11-synthase (CBS) (Mudd 1989; Sebastio et 
a/. 1995), in 5,1 0-methylenetetrahydrofolate reductase (MTHFR) (Goyette eta!. 1995) 
and in methionine synthase (MS) (Leclerc eta/. 1996) can cause elevated plasma 
homocysteine levels leading to homocystinuria. This suggests that defective genes in 
the folate-dependent homocysteine pathway (Figure 16) may be involved in the etiology 











tetra hvdrofo late 
Methionine S\ltlthase 
5. I 0-rnethylene 
tetrahydrofolate 
reductase 




Figure 16- Pathways of homocysteine metabolism 
1.5.2 5,1 0-Methylenetetralhydrafolate reductase 
The folate-dependant enzyme, 5, 1 0-methylenetetrahydrofolate reductase 
(MTHFR) (EC 1.5.1.20), is one of the principal means by which cells regulate 
intracellular concentrations of methionine and homocysteine. This enzyme catalyses 
the conversion of 5, 1 0-methylenetetrahydrofolate into 5-methylenetetrahydrofolate, the 
predominant circulatory form of folate, for use as a carbon donor for the remethylation of 
homocysteine to methionine (Frosst eta/. 1995). The MTHFR gene was first isolated 
and mapped to chromosome ·1 p36.3 by Goyette eta/. (1994) in which Frosst and 
colleagues (1995) first identified the cytosine to thymine (C-+ T) transition in nucleotide 
position 677. This polymorphism leads to the substitution of an alanine to valine residue 
(Frosst eta/. 1995) and is considered an autosomal recessive mutation (Bailey and 
Gregory 1999b ). 
The presence of the mutation in the homozygous state correlates with increased 
MTHFR thermolability and a 50% reduction in enzymatic activity (Kang eta/. 1991; 
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Rozen 1996; van der Put eta/. 1996; Volcik eta/. 2000). Decreased MTHFR activity is 
associated with elevated homocysteine and red blood cell folate concentrations and 
decreased plasma folate levels (Koch eta/. 1998; Melnick and Marazita 1998; Molloy et 
a/. 1997; Shaw eta/. 1998a; van der Put and Blom 2000; van der Put eta/. 1997b ). 
Homozygous mutant (TT) individuals have been reported to have significantly elevated 
plasma total homocysteine concentration compared to those who are homozygous (CC) 
and heterozygous (CT) (Bailey and Gregory 1999b; Friedman eta/. 1999; Frosst eta/. 
1995). High homocysteine levels have also been noted in children affected with SB and 
who are either heterozygous or homozygous for the polymorphism (Bjorke-Monsen et 
a/. 1997). The allelic frequency of the mutation in North America is approximately 35%, 
predisposing individuals to milld hyperhomocysteinemia when folate status is low 
{Christensen eta/. 1999; Frosst eta/. 1995; Jacques eta/. 1996). The mutation is the 
most frequent genetic cause for mild to moderate hyperhomocysteinemia especially 
during times of folate insufficiency (Clark eta/. 1998; Engbersen eta/. 1995; Frosst et 
a/. 1995; Kluijtmans eta/. 1996; van der Put eta/. 1998; Weisberg eta/. 2001 ). 
The homozygote (TT} !~enotype has been associated as a risk factor for NTDs in 
several studies. A Dutch study found a higher incidence of the MTHFR C677T mutation 
in patients and parents of SB cases than in the control samples (van der Put eta/. 
1995). Studies by Whitehead eta/. (1995), Shields eta/. (1999), Ou eta/. (1996), de 
Franchis eta/. (2002; de Franchis eta/. 1998a), Shaw eta/. (1998b), Kirke eta/. (1996) 
support their findings. Those 1individuals found to be homozygous for this mutation were 
found to have a three to sevenfold increased risk for a NTD, while the risk for 
heterozygous individuals for the mutation were only slightly elevated over those wild 
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type homozygotes (CC) (Kirke eta/. 1993; Ou eta/. 1996; van der Put eta/. 1995; 
Whitehead eta/. 1995). Botto and Yang (2000) concluded that homozygosity in infants 
is associated with approximatHiy a 70% increased risk for SB. 
Other studies that supported Botto and Yang's findings (2000) and have also 
demonstrated that there was a further increased risk for NTD associated with the 
MTHFR C677T polymorphism when the mother and child are homozygous for the 
variant allele (TT) (Christensen eta/. 1999; Pietrzyk eta/. 2003; Shields eta/. 1999; van 
der Put eta/. 1996; Volcik eta!. 2000). Johanning eta/. (2002) and Kirke eta/. (2004) 
also concluded an increased risk for NTDs in individuals who were heterozygotes and 
mutant homozygotes. Posey eta/. (1996) calculated that 13% NTD cases can be 
attributed to the MTHFR C677T mutation homozygote (TT); and a total of 24% if the 
allele contributes also in heterozygotes. 
Other studies however, failed to find evidence of association with MTHFR C677T 
in different populations such as Turkish, German and Mexican populations (Boduroglu 
eta!. 1999; Gonzalez-Herrera eta/. 2002; Johnson eta/. 1999; Koch et at. 1998; 
Stegmann eta/. 1999). These discrepancies may be caused by the variation of the 
MTHFR C677T frequency amongst different ethnic groups (Barber et at. 2000; Botto 
and Yang 2000; de Franchis E~t a/. 1998a; de Franchis et at. 1995; Franco et at. Jan 
1998; Frosst eta/. 1995; Monsalve eta/. 2003; Mornet eta/. 1997; Papapetrou eta/. 
1996; Pepe eta/. 1998; Shaw eta/. 1998b; Ubbink eta/. 1999; van der Put eta/. 1997a; 
Wilcken and Wang 1996). This observed high variability in the prevalence of the T 
allele suggests that the TT genotype may only be a risk factor for NTDs in some ethnic 
groups and not in others (Papapetrou eta/. 1996). 
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The heterozygotes (CT) and mutant homozygotes (TT) for the MTHFR C677T 
polymorphism produces a 50-GO% reduction in enzyme activity than the wild-type, 
however with an adequate level of folate in the diet, the mutant homozygotes (TT) can 
exhibit normal folate levels in the blood (Botto and Yang 2000). Therefore the mutation 
may only be a risk factor in populations with poor nutrition and low folate levels in the 
diet. This could explain the conflicting studies (Shields eta/. 1999). Nevertheless, a 
study conducted by van der Put and colleagues (1997a) observed frequencies in 
different populations and found that 9.2% of controls are homozygous (TT), while 14.5% 
of all mothers with a NT-affeded child are homozygous (TT), 15.5% of all fathers of a 
NT-affected child are homozy~~ous (TT), and 16.4% of NT-affected individuals are 
homozygous (TT). Thus, the study demonstrated a statistically significant association of 
a 2-fold increased risk for NTD (van der Put eta/. 1997a) and therefore should be 
regarded as a genetic risk factor for SB in some populations (Johnson eta/. 1999). 
A second polymorphism in the MTHFR gene has been characterised by van der 
Put and colleagues (1998) and Weisberg eta/. (1998). The polymorphic variant is 
described as an A to C transition at nucleotide position 1298 (A 1298C), resulting in a 
substitution of glutamate to alanine in the enzyme (van der Put eta!. 1998). The 
mutation is also associated with decreased enzyme activity (van der Put eta/. 1998; 
Weisberg eta/. 1998; Weisberg eta/. 2001) that is more pronounced in the homozygous 
genotype (CC) than in the heterozygous genotype (AC) or wild type (M), and does not 
result in a thermolabile protein (Friedman eta/. 1999). However, the effect of the 
MTHFR A 1298C mutation on the enzyme activity and homocysteine concentration is 
less than that of the MTHFR C677T mutation (Dekou eta/. 2001; Friedman eta/. 1999; 
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van der Brandhof 2001; van der Put and Blom 2000; van der Put eta/. 1998; Volcik et 
a/. 2000; Weisberg eta/. 1998). The allele frequency of the MTHFR A1298C 
polymorphism is similar to that of the MTHFR C677T polymorphism (Bailey and Gregory 
1999a); however unlike the MTHFR C677T, the MTHFR A1298C mutation in either the 
heterozygous or homozygous state does not seem to be associated with elevated 
homocysteine levels (lsotalo €!f a/. 2000; Medina and Amores-Sanchez 2000; van der 
Put et a/. 1998; Weisberg et a/. 2001 ). 
Vander Put et al. (199B) observed an increase in the frequency of the MTHFR 
A 1298C mutation in NTD-affected children. DeMarco eta/. (2002) determined that the 
prevalence of heterozygotes (AC) and homozygotes (CC) is increased among NTD 
patients and mothers. Trembath et al. (1999) also demonstrated a significant 
association between the MTHFR A1298C allele and the risk of SB. Furthermore, 
individuals who are compound heterozygotes for both the MTHFR A1298C (AC) and 
MTHFR C677T (CT) alleles tend to have a biochemical profile similar to that seen 
among MTHFR C677T mutant homozygotes (TT); with increased homocysteine levels 
and decreased serum folate levels (Weisberg et al. 1998). The MTHFR 677T allele is 
also nearly always found in trans or cis configuration with the MTHFR 1298A allele and 
the MTHFR 1298C allele with the MTHFR 677C allele (Parle-McDermott eta/. 2003b). 
The MTHFR C677T and MTHFR A 1298C polymorph isms have never been observed in 
a compound homozygous state (MTHFR 677TT/1298CC) (Barber eta/. 2000; van der 
Put eta/. 1998). Compound heterozygosity was also observed to cause mildly elevated 
homocysteinemia (van der Put et al. 1998; Weisberg et al. 2001 ). Studies have 
reported an increased prevalemce of the combined heterozygous genotype (MTHFR 
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677CT/1298AC) in NTD cases compared to controls (Akar eta/. 2000; Barber eta/. 
2000; Dekou eta/. 2001; lsotalo eta/. 2000; Parle-McDermott eta/. 2003b; Richter eta/. 
2001; Stegmann eta/. 1999; Trembath eta/. 1999; van der Put eta/. 1998). Almost a 
three-fold increased risk for combined heterozygous-mutated genotype among NTD 
case compared with the MTHFR 677CC/1298AA genotype. Vander Put eta/. (van der 
Put eta/. 1998) calculated that combined heterozygosity for both mutations was 
correlated with 28% of NTDs. However, other studies fail to support their findings 
possibly due to comparatively small sample sizes (Parle-McDermott eta/. 2003a; 
Yamada eta/. 2001). 
1.5.3 Methionine synthase 
Since both hyperhomocysteinemia and elevated vitamin 812 levels are 
independent indicators of NTD risk, focus has pointed towards a potential role for 
methionine synthase (Gaughan eta/. 2001; Kirke eta/. 1993; Scott 1994). The 
methionine synthase (MS) enzyme (EC 2.1.1.13), with the use of vitamin 812 as a 
cofactor and 5-MTHF as the methyl-group donor, catalyses the remethylation of 
homocysteine to tetrahydrofolate and methionine (Zhu eta/. 2003). Thus, a deficiency in 
MS or vitamin 8 12 should theoretically lead to increased plasma folate and plasma 
homocysteine suggesting its possible involvement in the etiology of NTDs. As well, 
maternal preconceptional dietary intake of methionine was associated to reduce the risk 
of NTD, thus supporting the role of methionine in NTDs (Shaw eta/. 2002). 
The methionine synthase gene is located on chromosome 1 q43sw and was first 
cloned, sequenced and the mutation identified by Chen, Leclerc, Li and colleagues 
(Chen eta/. 1997; Leclerc eta/. 1996; Li eta/. 1996b). A commonly observed genetic 
52 
polymorphism was an A to G transition at base pair 2756 that converts an aspartic acid 
into a glycine residue. Individuals who are deficient in this enzyme have high levels of 
homocysteine, low levels of plasma methionine, and clinical implications similar to those 
brought about by a deficiency of MTHFR activity (Frosst eta/. 1995; Harmon eta/. 1999; 
Mills eta/. 1995; Mills eta/. 1996) which may indirectly contribute to NTD risk (van der 
Put eta/. 1997c). 
Vander Put eta/. (2000) speculate that the combination of low vitamin 812, 
together with the MS A2756G mutation could result in a decreased methylation of 
homocysteine to methionine. The MS 2756AA genotype is found to be associated with 
a modest, but significant increase in homocysteine levels (Chen eta/. 2001; Harmon et 
a/. 1999). Christensen eta/. (1999) indicate that the homozygous mutant genotype (GG) 
conferred an increased risk for NTDs and the risk was further increased if both mother 
and child had this genotype. The MS 2756G allele frequency was observed to be 
slightly higher in SB patients, with a difference at the limit of statistical significance 
(Gueant-Rodriguez eta/. 2003). Zhu eta/. (2003) demonstrated that there was a higher 
frequency of the mutant geno1type (GG) among NTD cases. 
Johanning eta/. (2000) has reported that associations between the 677T MTHFR 
mutation and the A2756G MS polymorphism slightly increased NTD risk. Morrison eta/. 
(1998) also made a possible association with MTHFR in which mothers who had both 
variants (MS A2756G/ MTHFR C677T) were at increased risk for having a child with 
SB. Some studies fail to associate a risk with NTD (Brody eta/. 1999; De Marco eta/. 
2002; Morrison eta/. 1997; Shaw eta/. 1999; van der Put eta/. 1997c) however; these 
studies were relatively small with only sufficient statistical power to detect large effects. 
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1.5.4 Methionine synthas1e reductase 
Since methionine synthase reductase (MTRR) (EC 2.1.1.135) is responsible in 
maintaining methionine synthase in an active state, it has also been studied for its 
involvement in NTDs. A MTRR deficiency will adversely affect the function of 
methionine synthase (Brody eta/. 1999). The enzyme has been cloned by Leclerc and 
colleagues (1998) and localized to chromosome 5p15.2-15.3. A common polymorphism 
of the gene (MTRR A66G) has been identified, which substitutes an A to a Gin 
nucleotide position 66 causin~J the amino acid change from isoleucine to methionine. 
Individuals homozygous for the MTRR A66G mutation (GG) have been found to 
have hyperhomocysteinemia (Lucock eta/. 2001 ). This finding was supported by 
Gaughan eta/. (2001) who observed that a MTRR A66G polymorphism significantly 
influences the circulating homocysteine concentrations. While the MTRR A66G 
mutation combined with a low level of vitamin 812 was found to increase the risk of 
NTDs (Gueant-Rodriguez eta/. 2003; Wilson eta/. 1999). Zhu eta/. (2003) reported an 
association between the MTRR mutant genotype (AG or GG) and a threefold higher risk 
of NTD when compared to thE~ AA genotype. Pietrzyk and colleagues (2003) 
demonstrated that the presence of the MTRR 66GG genotype increases the risk of SB. 
Doolin eta/. (Doolin eta/. 2002) found evidence of an increased risk of SB in the 
offspring of women with the MTRR AG and GG genotype, relative to the AA 
homozygotes. Wilson eta/. (1999) observed that a combined genotype of MTHFR 
677TT with MTRR 66GG in children and mothers have a fourfold and threefold 
increased risk for SB respectively (Wilson eta/. 1999) which was supported by Pietrzyk 
eta/. (2003). An Italian study found an increased risk of NTDs only when the MTHFR 
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677CC genotype was combined with the MTRR 66GG genotype (Gueant-Rodriguez et 
a/. 2003) while Reitan eta/. (2003) also detected an interaction between MTHFR C677T 
and MTRR A66G in NTD easElS, which supported the observations of Wilson eta/. 
(Wilson eta/. 1999). They also observed a maternal (MTRR A66G)-fetal (MTHFR 
C677T) interaction which elevated the NTD risk (Reitan eta/. 2003). 
The presence of at least one high-risk allele (MS A2756G or MTRR A66G) is 
associated with an increased of SB in offspring and that this risk may be further 
increased when the mother is homozygous for the high risk allele (Doolin eta/. 2002). 
Zhu eta/. (2003) observed an exceptionally high frequency of double mutants of both 
MTRR and MS (AG and AG) among NTD cases. Some studies fail to make an 
association between MTRR variants in NTDs (Lucock eta/. 2001 ), however their studies 
were limited and a larger population study is needed to confirm their results. 
1.5.5 Cystathionine B-synthase 
Another key enzyme in homocysteine metabolism is cystathionine 11-synthase 
(CBS) (EC 4.2.1.22). CBS catalyses an irreversible condensation of homocysteine and 
serine to cystathionine using vitamin B6 as a cofactor (Mudd 1989; Quere eta/. 1999). 
Kraus and colleagues (1994) first sequenced the CBS gene located on chromosome 
21q22.3. CBS controls homocysteine levels by degrading homocysteine into 
cystathionine (Borcsok and Abeles 1982; Morrison eta/. 1998). Deficiency in enzyme 
activity leads to elevated levels of homocysteine as well as methionine in plasma and 
urine (Mudd 1989). Abnormalities of this gene may result in enzyme deficiency and 
hyperhomocysteinemia, which is now recognised as a risk factor for neural tube defects 
(De Franchis eta/. 1998b; Mills eta/. 1995; Sperandeo eta/. 1996; Tsai eta/. 1996). 
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The identification of a 68 base pair insertion in the coding region of exon 8 of the CBS 
gene (Figure 17) was first documented in a homocystinuria patient (Sebastio eta/. 
1995) which has led to the study for its involvement in the etiology of NTDs. Increased 
rate of fetal loss has been reported in women with homocystinuria due to CBS 
deficiency (Mudd eta/. 1985) and CBS abnormalities have been reported in a minority 
of NTD cases (Steegers-Theunissen eta/. 1991 ). 
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Figure 17- Cystathionine B-synthase Insertion 
Only a handful of studies have been done in regards to this mutation and its 
association with NTDs. Ramsbottom eta/. (1997) and Morrison eta/. (1998) fail to 
provide evidence for the insertion being associated with NTD in Irish, Dutch and British 
populations. In an Italian study, NTD patients homozygous for the MTHFR 677TT 
mutation was significantly associated with the CBS 844ins68 allele than the MTHFR 
677TT controls (de Franchis 1997). The majority of studies have focused on the CBS 
insertion alone and have not assessed the presence of the other mutations (gene-gene 
interaction) linked to NTDs. Sperandeo eta/. (1995) speculate that this insertion, in 
combination with the MTHFR 677TT homozygote, might further influence homocysteine 
metabolism. Ramsbottom eta/. (1997) reported a non-significant increase in the 
frequency of cases that were heterozygous for the CBS 844ins68 allele among those 
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who were MTHFR 677TT homozygotes. Botto and Mastroiacovo (1998) observed that 
homozygosity for the CBS mutation was not a NTD risk factor but they reported a five-
fold increased risk for NTD in iindividuals homozygous for the MTHFR C677T mutation 
combined with the CBS mutation. Relton eta/. (2004) found that the MTHFR C677T 
variant in combination with the CBS 844ins68 variant inflates the effect of the MTHFR 
C677T variant. This interaction is supported by Speer eta/. (1999) and de Franchis et 
a/. (2002). 
The CBS insertion event occurred fairly recently but it is found in all human 
populations (De Stefano eta/. 1998). It has been demonstrated that this mutation in its 
heterozygous state is highly prevalent (Tsai eta/. 1996); however its frequency varies 
extensively between ethnic and geographical backgrounds (De Franchis eta/. 1998b; 
Franco eta/. 1998). The ethnic variation is evident in the heterozygosity of the CBS 
gene mutant, which was found to be 13.5% in Caucasians while it was absent among 
Asians (Franco eta/. 1998). However the significant heterogeneity between populations 
provides the potential for this mutation to be used as an anthropogenetic marker that 
would be able to distinguish between some of the major human population groups 
(Pepe eta/. 1999). 
Gene-nutrient, gene-environment, and gene-gene interactions should be 
considered in the etiology of NTDs. Numerous studies have indicated that the 
possession of more than one polymorphism at folate-dependant loci can elevate the risk 
of NTD (Morrison eta/. 1998; van der Put eta/. 1998; Wilson eta/. 1999). Gene-gene 
interactions of seemingly neutral mutations might be related to the etiology of NTD (van 
der Put eta/. 2001 ). 
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1.6 Mutation Detection 
The methodological approach I developed uses existing multiplex polymerase 
chain reaction technology and fluorescent single nucleotide extension (SNE) methods. 
The SNE system used here is the single nucleotide polymorphism detection analysis 
system, called SnaPshot™(Applied Biosystems). This approach includes the use of 
capillary electrophoresis coupled with Genescan® analysis software. 
My project involves the optimisation of three multiplex PCRs including an initial 
multiplex PCR, a multiplex hemi-nested PCR and a multiplex single base extension or 
SnaPshot™ PCR. Each of the PCRs was performed consecutively and optimised to 
detect very low quantities of DNA and fragmented or damaged DNA. The fragment 
analysis was performed using capillary electrophoresis detection coupled with 
Genescan® analysis software. All three multiplex PCRs, used together, can serve as a 
novel tool to detect five of the mutations linked to neural tube defects rapidly with high 
specificity and sensitivity. 
1.6.1 Nested and hemi-nested Polymerase Chain Reaction 
Nested or hemi-nested PCR can be used following purification of the initial PCR 
product. The initial PCR product is used as template DNA for the successive round of 
PCR. The process can use one of the initial primers and a new primer (hemi-nested 
PCR) or two new primers (nested PCR), whose sequences are found inside the PCR 
product from the first reaction. This second PCR is intended to amplify a smaller 
secondary fragment primed within the first PCR product (Figure 18) (Mullis eta/. 1986). 
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The nested PCR method, first demonstrated by Beck and Ho (1988), can be 
employed to improve sensitivity and specificity (Haqqi eta/. 1988). Specificity can be 
increased as It would be unlikely that non-specific PCR products would contain the 
binding sites for the new primors (McPherson 2000). The second round of 
amplification increases sensitivity by producing a greater yield of the desired amplicon. 
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Figure 18- Schematic of Nested and Hemi-nested PCR 
An approximate 104 enhancement of the target region can be obtained 
(McPherson 2000). This step can overcome amplification failure due to degradation 
which is ideal when working with degraded or ancient DNA that do not contain large 
amounts of intact regions of DNA greater than 200 base pairs (Hummel 2003). 
1.6.2 Sequencing Polymerase Chain Reaction 
Sequencing analysis permits the identification of the succession of bases within 
an amplified DNA fragment de~tecting all types of polymorphisms (Hummel 2003). Many 
techniques have been developed, however the automated Sanger sequencing method, 
first described by Sanger (Sanger eta/. 1977b ), is the most commonly used today. A 
sequencing PCR requires a second amplification following the initial PCR that amplifies 
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the target region(s). A purification step is usually performed prior to and following the 
sequencing PCR to remove any unincorporated dNTPs, ddNTPs and primers. This 
PCR, sometimes referred to as an asymmetrical PCR, differs in that it requires only one 
primer resulting in a linear growth of single stranded DNA (Sanger eta/. 1977b). The 
reaction mixture contains all the same reagents as the initial PCR plus fluorescently 
labelled dye-'terminating' 2', 3'-dideoxynucleotide triphosphates (ddNTPs). Thus, 
ddTTP, ddCTP, ddATP, ddGTP are labelled with a red, blue, green, and yellow 
fluorescing dye respectively. During polymerisation, the DNA polymerase adds dNTPs 
complementary to the template. When a ddNTP is incorporated rather than the 
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Figure 19- An example of a sequencing electropherogram generated from the ABI 3100 
corresponding dNTP, elongation terminates due to the absence of a hydroxyl group at 
the 3'-end of the ddNTP. This prevents the formation of the next phosphodiester bond 
necessary for DNA extension (McPherson 2000). This incorporation occurs randomly 
at all sites of the amplified PCR product resulting in single-stranded products of variable 
lengths representing all possible product length (primer +1 to primer +n). The single 
stranded amplification products are then electrophoresed via capillary electrophoresis 
and sorted by length, resulting in a succession of peaks of different colors representing 
the sequence of interest (Figure 19) (Li eta/. 1999; Rosenblum eta/. 1997). 
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1.6.3 Single Nucleotide Extension Polymerase Chain Reaction 
A single nucleotide extension PCR (SNE-PCR), also known as mini-sequencing, 
involves the extension of an oligonucleotide by a single base with the aid of a DNA 
polymerase (Fiorentino eta/. 2003; Syvanen eta/. 1990; Tully eta/. 1996). This project 
uses a commercially available kit from Applied Biosystems called SNaPshot™ (Applied 
Biosystems, Foster City, CA, USA) in which the methodology was first described in 
detail by Turner et at. (2002). This technique is employed to identify a known 
polymorphism without having to sequence the entire PCR product, while still 
maintaining the same qualitative characteristics of sequence analysis (Fiorentino eta/. 
2003). It requires an initial amplification of a DNA fragment containing the polymorphic 
site of interest, which serves as template for the SNE-PCR. Following the initial PCR, 
the amplification products are purified with shrimp alkaline phosphatase (SAP) and 
exonuclease 1 (EX01) enzymes to remove any remaining single-stranded primers and 
unincorporated dNTPs that could interfere with the subsequent reaction (Butler 2005). 
The SNE-PCR requires the same cyclical steps as a typical PCR (Figure 20). The 
SNaPshot™ kit includes the fluorescent labelled ddNTPs, buffer and DNA polymerase 
compatible with any primer set. The SNE-PCR primers are specifically designed to be 
one base contiguous to the polymorphic site in either the forward or reverse orientation. 
Therefore, the primers anneal immediately 5' of the polymorphism and initiate the 
single-base extension reaction. The DNA polymerase extends the SNE primer by one 
base with a fluorescently dye-labelled terminating ddNTP, thus ending extension. 
Similar to sequencing PCR, each of the four nucleotides (ddNTPs) have their own dye 
color. The SNE-PCR undergoes 25 or more cycles to permit linear amplification of 
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Figure 20- SNaPshot™ PCR Kit process (Applied Biosystems 2001) 
fluorescent ddNTP addition to the SNE primer by the DNA polymerase. After the SNE-
PCR is complete, the PCR products are purified with SAP to remove unincorporated 
fluorescent ddNTPs that could cause dye blobs and artifacts during capillary 
electrophoresis rendering the electropherogram difficult to interpret. The final products 
are separated by size via capillary electrophoresis in which the fluorescence is 
detected. The products are then analysed and the genotype is determined by 
identifying which dideoxynucleotide was incorporated at the polymorphic site. The 
color of the peak indicates the nucleotide present at the site of interest while the position 
of the peak correlates to the SNE primer's size plus one base pair and is used to 
differentiate the various SNP primers. One of the advantages of the SNE-PCR is that 
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multiple polymorphisms can be analysed in parallel, known as a multiplex SNE-PCR, by 
separating the primers according to size and observing the incorporation of 
fluorescently-labelled ddNTPs (Tully eta/. 1996). 
1.6.4 Multiplex Polymerase Chain Reaction 
A multiplex PCR uses two or more primer sets to amplify multiple target regions 
simultaneously within a single reaction (Edwards and Gibbs 1994 ). The primers amplify 
unique regions of DNA, both in individual pairs and in combinations of many primers, 
under a single set of reaction conditions (Markoulatos eta/. 1999). This method was 
first described by Chamberlain eta/. (1988) and has since proven a valuable tool in both 
clinical and research laboratories. The use of multiple primer sets saves sample 
material, time and effort, as well as cost. This approach also reduces the risk of 
contamination and increases throughput. In order for an accurate multiplex to be 
successful, a prerequisite is optimisation that involves strategic planning and multiple 
attempts (Markoulatos eta/. 2002). 
1. 7 Development and Optimisation of Multiplex Methods 
The development of an efficient PCR system requires strategic planning and 
extensive optimisation. This may take multiple attempts and various experiments to 
optimise the reaction conditions. Optimisation demands a delicate balance between 
the consistent and equal amplification of specific products and avoiding the production 
of non-specific products (Harris and Jones 1997). Optimisation can be easily obtained 
with one set of primers; however, with multiple primer sets a substantial amount of 
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optimisation is required. The addition of each new primer in a multiplex PCR reaction 
exponentially increases the complexity of possible primer interactions as well as the 
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Figure 21 -Multiplex Step-by-step approach (Henegariu eta/. 1997). 
chance of generating non-specific artifacts (Brownie eta/. 1997; Butler eta/. 2001 ). 
These non-specific products may be amplified more efficiently than the desired target, 
consuming reaction components necessary for the desired targets. This not only 
decreases the PCR efficiency and sensitivity, but also makes analysis of the results 
more difficult. Thus, the optimisation of multiplex PCR should aim to minimise or reduce 
such non-specific interactions. 
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The development of an optimised multiplex PCR typically faces several 
challenges and difficulties including poor sensitivity and specificity, and/or preferential 
amplification of specific targets (Markoulatos eta/. 2002). A successful multiplex PCR 
reaction requires the relative concentration of the primers, concentration of the PCR 
buffer, balance between the magnesium chloride and deoxynucleotide concentrations, 
cycling temperatures, and the amount of template DNA and DNA polymerase to be 
determined (Markoulatos et al. 2002). The two most critical factors in a highly specific 
and efficient multiplex PCR are primer design and optimal annealing temperature 
(Markoulatos eta/. 2002). 
1.7.1 Primer Design 
A successful multiplex PCR enables similar amplification efficiencies for all the 
primer pairs and their respectlive targets. Each additional primer set in the reaction 
provides challenges to optimising the technique, challenges such as primer interference 
and the increase of non-specific priming. However, these difficulties can be overcome 
with the design of compatible and specific primer sets that achieve a balance between 
specificity and efficiency (Dieffenbach eta/. 1993). Thus, primer sensitivity and 
specificity are the most important aspects of multiplex development. Many factors must 
be considered while designing primers (Dieffenbach eta/. 1993; Nicodeme and Steyaert 
1997; Robertson and Walsh-\Neller 1998; Shuber eta/. 1995; Wu eta/. 1991 ). Here are 
a few suggested primer design guidelines: 
a) Primers should be sequence specific and should fully match the intended 
hybridisation sites. Detailed sequence information for primer binding sites is 
important in order to avoid non-specific amplification at other sites with similar 
65 
sequences and primer-template mismatch sites (Dieffenbach et at. 1993). To 
examine the similarity of the primer to other known sequences that may result in 
multiple binding sites for the primer and to verify the uniqueness of the primer 
sequence, a BLAST search can be conducted in GeneBank via the internet at 
http://www.ncbi.nlm.nih.gov/BLAST (Altschul et at. 1997) (Butler 2005). 
b) Given that all primer sets must function under a single set of experimental 
conditions it is essential that they are designed to have nearly identical melting 
temperature (Dieffenbach eta/. 1993). 
c) Primers should be between 18-30 bp in length (Harris and Jones 1997) and 
similar in size and nucleotide ratios. The shorter the primer, the more quickly it 
will anneal to the target DNA and form a stable double-stranded molecule to 
which the DNA polymerase can bind and begin synthesis (Dieffenbach eta/. 
1993). However, long primers allow a higher annealing temperature and produce 
less non-specific products. 
d) The G/C content should range from 35-60% (Gibbs 1989; Henegariu eta/. 1997). 
Lower G/C contents lead to poor amplification, while higher contents lead to non-
specific amplification products. 
e) Primers within the multiplex should not display significant homology either 
internally (hairpin structure) or to one another (primer-primer interactions). 
Complementarity at the 3'ends of any of the primers should be avoided as this 
promotes the formation of undesirable primer-dimer artifacts (Dieffenbach eta/. 
1993; Henegariu et at. 1997). These primer artifacts, which deplete the reaction 
of dNTPs and primers and compete for the DNA polymerase, the multiplex's 
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desired am pi icons for polymerase, result in a lower yield of the desired product 
(Bourque eta/. 1993; Vandenvelde eta/. 1990). 
f) If possible, primers should contain a 3'-terminal "G/C clamp" (one or two Gs 
and/or Cs at the 3' end) (Sharrocks 1994). A 3' G/C clamp is to ensure the 3'end 
has a stronger bonding than the rest of the primer due to the 3 hydrogen bonds 
that form between G's and C's. Without a 3' terminal G/C clamp there is a risk 
that the DNA polymerase will not bind and extend the product efficiently. 
g) However, runs of three or more Cs or Gs within the primer should be avoided 
especially at the 3'end. Homopolymeric stretches of G or C could promote rich 
sequences, primer dimer or the formation of secondary structures within the 
primer. Along with homo polymeric stretches of the four bases, repeated motifs 
or palindromic sequences should also be avoided (Sharrocks 1994 ). 
1.7.2 Cycling Parameters 
Each step of the PCR influences the efficiency and specificity of the amplification 
and therefore has a direct relation on the yield of the desired amplicon. 
Denaturation 
Denaturation is influenced by the sequence of the DNA template. Templates that 
are G/C rich require a higher denaturation temperature due to the increase in hydrogen 
bonds between the nucleotide~s. Incomplete denaturation of the target template and/or 
the PCR product is the most likely cause for PCR failure. If the temperature is too low, 
the DNA template fails to denature completely and returns to its more stable double-
stranded configuration (Harris and Jones 1997). This reassociation prevents efficient 
primer annealing and DNA extension. However, if the temperature is too high or 
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denaturation length is too long, DNA polymerase activity will be lost due to temperature 
inactivation. Both extremes reduce the yield of the desired amplicon. An initial hot start 
step can be used prior to the regular PCR cycling to ensure that all large molecules are 
denatured and to eliminate non-specific reactions (production of primer-dimers) (Chou 
eta/. 1992). 
Anneal 
The annealing step is considered to be one of the most important parameters 
during PCR optimisation (Markoulatos eta/. 2002). The success of a PCR relies heavily 
on the specificity with which a primer anneals to its target sequence therefore it is 
important to optimise this molecular interaction. Stringent annealing temperatures, 
especially during the first several cycles help to increase specificity, thus increasing the 
overall yield of amplicon. The annealing temperature (T a) and length of time required is 
dependent on the melting temperature (T m), base composition, length and concentration 
of the primers (Harris and Jones 1997). Determining an optimal Ta begins with 
calculating the melting temperatures (T m), the simplest method being 
T m= [(number of G+C) x 4'C +(number of A+ T) x 2'C] (McPherson 2000). This 
calculation is an approximation because Ta is affected by buffer components and primer 
and template concentrations (Roux 1995). When employing multiple primer sets, a 
similar T a is important to avoid preferential amplification. If one primer anneals 
preferentially at the temperature chosen, the desired exponential amplification would not 
occur. TheTa is usually about S'C below the true T m of the primers (Henegariu eta/. 
1997) followed by performing temperature gradients to determine experimentally the 
optimal Ta. The optimal Ta is a compromise between hybridisation specificity of the 
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actual primers and full reaction efficiency (Hummel 2003). A low Ta tolerates more 
mismatches between the template and primers, resulting in a increased amplification of 
different products (artifacts) due to mis-priming to non-complementary sequences and 
non-specific amplification (McPherson 2000). These products are observed as PCR 
products or bands seen above or below the targeted amplicon on gel electrophoresis 
(Harris and Jones 1997). A higher T a adds more specificity to the process by reducing 
the amount of incorrectly annealed primers. However, it also reduces the overall 
efficiency because primers with a lower Ta fail to anneal and thus, do not produce 
amplification product (Dieffenbach eta/. 1993; Harris and Jones 1997). A rule of thumb 
in choosing the optimal tempe~rature is to select the highest temperature possible 
without reducing the sensitivity (Markoulatos eta/. 1999). 
Extension 
This step is traditionally performed at 72°C because it is the optimal temperature 
for Taq DNA polymerase activity. However the specific temperature can change 
depending on the DNA polymerase as DNA polymerases from other species have 
different optimal extension temperatures. The extension time depends upon the length 
and concentration of the target sequence. In multiplex PCR, as more loci are 
simultaneously amplified, the pool of DNA polymerase and nucleotides becomes the 
limiting factor and more time is necessary for the DNA polymerase to complete 
synthesis of all the products (Henegariu et a/. 1997). Therefore, longer extension times 
can be added at the end of cycling to ensure complete extension of all amplified 
products (Harris and Jones 1997). Longer extension times are also helpful in early 
cycles if the substrate concentration is very low and in later cycles when product 
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concentration exceeds enzyme concentration. Longer extension and annealing times 
can result in non-specific amplification (Chamberlain 1991 ). 
Number of Cycles 
The number of cycles influences both specificity and efficiency and the optimal 
number of cycles varies depending on the amount of the initial template, the primers 
used and the success of each amplification step. Increasing the number of PCR cycles 
increases the efficiency of amplification but reduces the overall specificity (Harris and 
Jones 1997). It can lead to the generation of both specific and non-specific products 
such as smears composed of high molecular weight products rich in single-stranded 
DNA (Bell and DeMarini 1991 ). Too many cycles can increase the amount and 
complexity of non-specific background products while too few cycles give low product 
yield. Between 25 and 35 cycles are usually used for modern samples while 40-60 
cycles can be used for ancient samples. After 60 cycles, the DNA polymerase activity 
decreases as the enzyme looses activity. Greater sensitivity can be achieved by using 
nested PCR rather than performing more than 40 cycles (Brisco eta/. 1990). 
1. 7.3 PCR components 
After cycling parameters are optimised, the concentration of each PCR reagent 
such as DNA template, primers, DNA polymerase, buffer, dNTPs and MgCb is 
investigated experimentally. 
Template Amount 
Ideally, the initial template should be void of any PCR inhibitor, which could 
negatively affect amplification efficiency, and should not contain high concentrations of 
chelating agents such as EDTA, or negatively charged ionic groups such as 
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phosphates, which can reduce the available Mg2+ ions (Harris and Jones 1997). As 
well, the template should be intact over the length of the region to be amplified, a 
challenge often encountered when working with degraded DNA. During optimisation, 
the primer-to-template ratio may need to be adjusted. Primers must usually be in a 107 
molar excess with respect to template (Markoulatos eta!. 2002). If the ratio is too high, 
primer-dimers form, this occurs with low template concentrations or excess primer 
concentrations. High concentrations of DNA can also lead to non-specific amplification 
products (Harris and Jones 1 997) as well as the generation of smears (Roux 1995). 
Too much DNA also disrupts the relative intensity of the bands and increases the 
hazard of false-positive amplification, while too little DNA produces weak or 
undetectable bands (Chamberlain 1990). It must be noted that degraded templates will 
give weaker signals for longer amplicons (Chamberlain 1992). 
Primers 
Primer pairs that function well in a singleplex reaction can be combined in a 
multiplex reaction and the relative performance of each primer set monitored. Primer 
concentration is a critical parameter for a successful PCR and must be refined 
experimentally in a multiplex when adding new primer sets (Markoulatos eta/. 2002). 
Preferential amplification of one target sequence over another is a typical occurrence 
when optimising a multiplex PCR (Mutter and Boynton 1995). The most common 
approach to balancing the amount of each product is to simply begin with equimolar 
primer concentrations. If the targeted am pi icons do not produce uniformly intense 
bands for all fragments, the concentration of the relevant primer sets in relation to the 
others should be adjusted by increasing the amount of primers for the "weak" loci and 
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decreasing the amount for the "strong" loci (Henegariu eta/. 1997; Markoulatos eta/. 
2002). The final concentrations of primers may vary considerably among loci 
(Markoulatos eta/. 1999). Hig1her primer concentrations may promote mis-priming and 
accumulation of non-specific product and may increase the probability of generating 
primer-dimers (Markoulatos eta/. 2002). As well, increasing the concentration of the 
primers does not necessarily improve the yield of specific amplicons, but amplification 
efficiency is compromised if concentration is too low (Harris and Jones 1997). 
Empirical testing have to be used when testing several primer pairs, because 
there are no means to predict the performance characteristics of a selected primer pair 
even among those that satisfy the general parameters of primer design (Henegariu et 
a/. 1997). 
Magnesium ions and dNTPs 
Magnesium ions and dNTPs influence both efficiency and specificity of the 
amplification process. Their requirements generally increase with the number of target 
amplicons in the multiplex, thE3refore, the concentrations must be optimised since each 
primer pair may have different requirements (Chamberlain 1991 ). Optimal Mg2+ will 
depend on the dNTP concentration, specific template DNA, and sample buffer 
composition; if they contain chelators such as EDTA, the optimal Mg2+ chloride 
concentration will change (Markoulatos eta/. 2002). The concentrations of MgCb and 
dNTP concentrations are dependent on each other as well as on the concentrations of 
primers. Magnesium chloride concentration needs only to be proportional to the amount 
of dNTPs (Henegariu eta/. 1997; Markoulatos eta/. 2002) The MgCb concentration 
must be a few millimolars higher than the nucleotide concentration (Harris and Jones 
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1997) since dNTPs and primers bind to free Mg2+ ions (Markoulatos eta/. 2002). In 
addition, Taq DNA polymerase is a magnesium-dependant enzyme that requires 
available Mg2+ ions for proper activity. Therefore, any change in dNTP concentration 
affects the concentration of available Mg2+ ions (Roux 1 995). Lower dNTP 
concentrations can lead to a considerable increase in the formation of primer artifacts 
as a consequence of excess free Mg2+ and to inconsistent amplification results which 
will frequently produce only a portion of the targeted am pi icons (Markoulatos et a/. 
1999). The best results were found to be between 200 and 400 ~M per each dNTP 
(Markoulatos eta/. 2002). Increasing MgCI2 concentration improves the efficiency but 
reduces the specificity of amplification (Harris and Jones 1 997). Excessive Mg2+ 
concentration stabilises the DNA double strand and prevents complete denaturation of 
DNA, which reduces yield. It can also reduce the fidelity of Taq DNA polymerase and 
lead to non-specific amplification products (McPherson 2000). On the other hand, 
inadequate Mg2+ reduces the amount of product (Markoulatos eta/. 2002). 
Buffer 
Taq DNA polymerase suppliers provide an appropriate buffer which has already 
been optimised. Increasing the concentration can sometimes improve efficiency of the 
multiplex reaction. Primer pairs with longer amplification products work better at lower 
salt concentrations; whereas primer pairs with short amplification products work better 
at higher salt concentrations I[Henegariu et a/. 1 997). 
Taq DNA Polymerase 
Enzyme requirements may vary with respect to individual target templates or 
primers and in particular the quality of the extracted DNA (Harris and Jones 1 997). 
73 
High concentrations of DNA polymerase do not necessarily result in higher yields of the 
desired amplicons (Harris and Jones 1997). It can result in unbalanced amplification 
and a slight increase in non-specific background products (Henegariu eta/. 1997). 
Insufficient amounts of the desired product will be produced if the enzyme is in low 
concentrations. No product bands or weak bands may indicate too little enzyme 
(McPherson 2000). 
Additives 
Poor or non-existent amplification may indicate the presence of inhibitors in the 
DNA sample (Raux 1995). PCR additives can be introduced in the reaction mixture tO 
enhance primer annealing specificity, reduce mismatch primer annealing and improve 
product yield and length (McPherson 2000). Additives can be chemicals or 
commercially available reagents that influence the secondary structure of DNA, the 
hybridisation of the primers, the removal of inhibitors and the activity of DNA 
polymerase (McPherson 2000). The formation of secondary structures within regions of 
template DNA during the extension process can be prevented by the addition of 
additives which reduce DNA polymerisation (Hengen 1997). Further action of these 
additives, as it interacts with DNA, is to modify hybridisation which could benefit by 
reducing the melting temperature of GC-rich sequences and increasing the resistance 
of the DNA polymerase to denaturation (Hengen 1997; Rees eta/. 1993). Available 
PCR additives that have been reported to improve the performance of multiplex PCR 
include: bovine serum albumin (BSA), glycerol, dimethyl sulfoxide (DMSO), formamide, 
and betaine (Bachmann eta/. 1990; Hung eta/. 1990; Markoulatos eta/. 2002; Pomp 
and Medrano 1991; Sarkar eta/. 1990; Seta 1990). These additives can benefit 
74 
multiplex PCRs but should be tested under different conditions to assess their 
usefulness in each case (Henegariu eta/. 1997). 
1.7.4 Troubleshooting 
The prerequisite to a successful multiplex PCR is optimisation. There are many 
articles, books and protocols available as aids in optimizing a multiplex reaction (Figure 
21) (Henegariu eta/. 1997; Markoulatos eta!. 2002; McPherson 2000; Rompler eta/. 
2006). 
1.8 Project Aim 
There are numerous genetic mutations and polymorphisms that have been linked 
to NTDs. The aim of my research is to design a novel detection system to analyse five 
single nucleotide polymorphisms that have been shown to be linked to NTDs. The 
objective is to design, develop and optimise a method for detecting molecular variations 
that may cause NTDs by using the latest technology of mutation detection analysis. The 
developed genetic technique must be rapid, specific and sensitive. The single 
nucleotide extension (SNE) method is extremely rapid as it only requires the extension 
of one single base to the amplification product. It is highly specific depending on the 
primer system being used. Here additional steps of hemi-nested PCR have been 
incorporated to increase test specificity. The addition of the hemi-nested PCR step will 
also increase the sensitivity allowing application to degraded DNA samples. As part of 
the development and optimisation of this technique, four different types of samples were 
analysed, modern DNA, experimentally degraded DNA, archived medical specimens 
and archeological samples. 
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The simultaneous detec1tion of five markers linked to NTDs has not been 
previously developed and this study would be the first of its kind. The advantage for 
detecting all five markers simultaneously is that the linkage between each of the 
mutations and the etiology of the associated NTD can be ascertained much faster than 
if independent detection systems were performed. The comparison of various types of 
sample sources should aid in establishing a relationship between the mutations and the 
condition thus, explaining why certain individuals are more prone to inherit this complex 
multifactorial genetic condition than others. Also, with samples of different 
chronological state, the methodology must be sensitive in order to analyse allelic 
sequence variations on degraded or damaged DNA. This type of analysis could also 
aid in understanding the evolutionary associations of the disease and identify the 
historical and contemporary distributions and abundances of the disease in human 
populations. This genetic research could one day lead to gene therapy and new 
practices that can alleviate the suffering associated with this condition. It could also be 
the basis for a novel genetic test with the purpose of facilitating clinical diagnosis and 
prenatal testing. 
1.8.1 DNA Damage and Degraded DNA 
In living organisms, DNA is continuously being damaged. This damage is 
repaired by enzymatic repair processes (Lindahl 1993). However, after death, these 
repair and maintenance processes cease and many destructive processes continue 
resulting in rapid DNA degradation. DNA degradation rates are dependant on the 
manner in which the organism dies and the post mortem taphonomy (Hofreiter eta/. 
2001 a; Hoss et at. 1996; Lindahl 1993; Paabo 1989). In the case of medical specimens, 
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biopsies and test samples, DNA degradation depends on the method of preservation 
employed and the storage conditions (Greer et at. 1991 ); Kim 2003; Taubenberger eta/. 
1997). 
Post-mortem and extracorporeal DNA is subject to degradation by cellular 
nucleases, lytic enzymes, lytic chemicals and hydrolytic damage based on cellular water 
content, free radical and oxidative damage (Hofreiter eta/. 2001 a; Lindahl 1993; Paabo 
eta/. 2004). Many features can affect the rate of DNA degradation like exposure, water 
content and temperature (Lindahl 1993). While rapid dessication can occur at low 
temperature or high salt concemtration which can slow the destructive processes and 
DNA degradation (Hofreiter eta/. 2001 b). DNA damage includes either base 
modification (oxidation and deamination), base loss, strand breaks or crosslinks (Hoss 
eta/. 1996; Lindahl 1993; Paabo 1989). The resulting DNA is degraded and/or 
fragmented which can interfene with PCR amplification. DNA damage studies have 
shown that the molecules are reduced to a size of some hundred base pairs with most 
ancient DNA extracts not revealing significant amounts of intact targets exceeding 200 
bp (Hofreiter eta/. 2001a; Hummel 2003; Paabo 1989). Previously, when ancient DNA 
was identified to be fragmented to less than 80-100 bp it was deemed unsuitable for 
analysis. However, with SNE-PCR what previously was deemed unsuitable is now 
viable for informative analysis. However after long enough time, no useful molecules will 
remain due to the cumulative effects of DNA damage (Hofreiter eta!. 2001 b). 
The invention of PCR (Mullis eta/. 1986) has made it possible to study and 
recover information from degraded and fragmented samples as well as low copy 
number DNA samples. Low copy number (LCN) DNA is often defined as samples 
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containing less than 100 pg of genomic DNA that is below the stochastic threshold level 
where PCR amplification is not as reliable for normal interpretation (Butler 2006). 
Characteristics of degraded and LCN DNA make it almost impossible to obtain long 
amplification products (Handt eta/. 1994 ). Therefore, the use of smaller am pi icons 
enhances DNA recovery and the small amplicons are more likely to be amplified in 
samples containing degraded DNA (Butler 2005; Chung eta/. 2004; Wiegand and 
Kleiber 2001 ). 
One of the challenges of working with degraded DNA is the increased chance for 
contamination (Gill 2001 ). A sterile laboratory environment is necessary to reduce 
contamination from reagents, exogenous DNA from casual contact or secondary 
transfer of samples, and from laboratory aerosols or amplification products. 
Contamination can be either systematic, from contaminated water or PCR buffer, or 
sporadic, from contaminated individual PCR tubes or individual samples. There are 
many published guidelines to working with degraded and LCN DNA that should be 
followed to reduce or prevent contamination (Butler 2005; Hofreiter eta/. 2001 b; Paabo 
eta/. 2004; Poinar 2003). 
Data interpretation is also more complicated due to the stochastic variation during 
PCR amplification. Difficulties include allelic drop-out, allelic drop-in (from 
contamination), and increased stutter products (Gill 2001; Gillet a/. 2000). Allelic drop-
out, also known as heterozygote imbalance, may occur if one allele of a heterozygote 
locus is preferentially amplified due to stochastic effects resulting in the complete loss of 
the other allele and is therefore interpreted as a homozygote genotype (Gill 2001 ). 
Allele drop-in, can sometimes be called stutter false alleles and can be produced by 
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contamination or non-specific amplification products due to an unoptimised amplification 
method (Butler 2005). Stutter products can be preferentially analysed and can be 
greater than the true allele (Gill 2001; Gill eta/. 2000). Typically an allele drop-in is not 
reproducible and thus by repeating the process multiple times without obtaining identical 
results, the problem can be identified as allele drop-in. This phenomenon is usually due 
to sporadic contamination (Budowle 2001 ). 
79 
2 Materials and Methods 
2.1 Samples 
DNA extracts from four types of samples were used: modern samples, 
experimentally degraded samples, medically archived samples and archeological 
samples. The modern sample was used primarily to develop and optimise the methods. 
The modern extracts are all from hair samples with a visible root sheath, from one 
individual with a known genotype for all of the markers being analysed. Various 
degraded samples were used to assess and ensure the sensitivity and specificity of the 
optimised protocol. The experimentally degraded samples were used in the optimisation 
stage predominantly, while the1 medical and archeological samples were used to assess 
the sensitivity and specificity of the developed method (Table 1 ). The experimentally 
degraded samples were blood samples from various donors, not known to suffer from 
NTDs that were treated to mimic degraded samples. Hydrolytic damage was generated 
by exposure to water at acidic pH (5.0). Oxidative damage was generated by exposure 
to bleach and ultra-violet radiation. The experimentally degraded samples were stored 
at -20'C. The preparation of these samples was not performed as part of this thesis 
and the resulting degraded DNA was provided. Ten samples in total were used. The 
medical archive samples were blood samples collected on FTA gene cards stored at -
20'C. There were five medicallly archived specimens in this study. My project included 
samples demonstrating both physiological aspects of NTD and samples without any 
manifestations in order to establish a link. The samples exhibiting physical signs of 
being affected with NTD include ancient skeletal and tooth samples. 
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Table 1- Sample Information 
Sample# Sample Type Tissue Source 
1 Modern Sample Hair LC 
2 Experimentally Degraded Sample Blood TJ 
3 Experimentally Degraded Sample Blood RS 
4 Experimentally Degraded Sample Blood AL 
5 Experimentally Degraded Sample Blood RCP 
6 Experimentally Degraded Sample Blood AT 
7 Experimentally Degraded Sample Blood AH 
8 Experimentally Degraded Sample Blood Ll (1/10) 
9 Experimentally Degraded Sample Blood CB (1/10) 
10 Experimentally Degraded Sample Blood R (1/10) 
11 Experimentally Degraded Sample Blood CH 
12 Medical Archive Sample Blood on FT A Card AD 
13 Medical Archive Sample Blood on FT A Card DD1 
14 Medical Archive Sample Blood on FT A Card DD2 
15 Medical Archive Sample Blood on FT A Card JZ 
16 Medical Archive Sample Blood on FT A Card YB 
17 Ancient Sample Bone, Tooth Burial #20 
18 Ancient Sample Bone, Tooth Burial #37 
19 Ancient Sample Bone, Tooth Burial #40 
20 Ancient Sample Bone, Tooth Burial #41 
21 Ancient Sample Bone, Tooth Burial #6 
The ancient skeletal and teeth samples were archeologically recovered by Richard 
Stallings, from two archeological sites in the Tunica County, Mississippi: the Austin site 
and the Bonds site (Table 2}. 
Table 2- Detailed information of Ancient samples 
Sample Site Burial# Sex Estimated A~e Additional Information 
17 A22-TU-549 20 F 11-12 Pathological hands and feet; has spina bifida occulta (SBO) 
18 A22-TU-549 37 M 30 +/- Has spina bifida occulta 
19 A22-TU-549 40 M 18-19 Has an open neural arch on his fifth lumbar; extensive SBO 
20 A22-TU-549 41 Unknown 9 Has spina bifida occulta child 
21 B22-TU-530 6 M 17-18 Has spina bifid occulta 
The Austin Site (-TU-549) is a ca. AD 1100-1250 village site that sits adjacent to 
an old Mississippi River channel cut-off. The Bonds site (-TU-530) is a sister site to the 
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Austin site and is located on the same Mississippi River cut-off a few miles north The 
Bonds site dates to the same time frame as the Austin site and it is suspected that the 
inhabitants may have had contact. Both sites yielded a number of individuals who had 
sacra which had unfused vertebral bodies as adults, although the neural arches were 
closed. 
2.2 Optimised Protocol 
2.2.1 Extraction and purification 
The extraction and purification procedures were performed at the Paleo-DNA 
Laboratory at Lakehead University in Thunder Bay, Ontario. The proteinase K method 
was used to extract DNA from the modern sample, the medical archived specimens and 
some of the experimentally degraded samples while the guanidinium thiocyanate 
method was used to extract some of the experimentally degraded samples and the 
archeological samples. 
2.2.1.1 Proteinase K and Modified Ethanol Precipitation Method 
Samples were extracted by using an overnight incubation on an Eppendorf 
Thermo mixer™ at 55·c in 500 ~L Extraction buffer (1 0% SDS, 0.5 M NaCI, 0.5 M 
EDTA, Tris-HCI1 M pH=8.0) (Hansen 1974). The following day, a 10% volume of 3M 
sodium acetate was added to the sample and mixed. Following the addition of a 2.5X 
volume of cold 95-100% ethanol, the tube was placed on ice for 30 minutes. The 
sample was then centrifuged for 5 minutes 13,000 r.p.m. and the supernatant 
discarded. Afterwards, 500 pL cold 95-100% EtOH was added to the tube and vortexed 
for one minute. The sample was then centrifuged for 10 minutes at 13,000 r.p.m. and 
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the supernatant discarded. The resulting pellet was allowed to dry for 30 minutes and 
was then resuspended in watE!r or TE buffer and incubated at 3TC for 15 minutes 
(Hayter 2007). 
2.2.1.2 GuSCN and Silica-bead Purification Method 
Samples were extracted by using an overnight incubation on an Eppendorf 
Thermomixer™ at 56°C in 500 IJL of GuSCN solution (Boom eta/. 1990). The following 
day, the lysed samples were incubated at 94 OC for 10 minutes and then centrifuged for 
one minute at 13,000 r.p.m. The supernatant was removed and placed into a sterile 1.5 
ml tube in which 900 IJL of GuSCN solution and 12-15 IJL of silica beads were added 
and vortexed briefly. The samples were placed on ice for 60 minutes and inverted 
every 15 minutes to resuspend the silica beads. The samples were then zip-spun 
(approximately 10 seconds) until clear and the supernatant removed and discarded. 
The silica beads were washed with 500 IJL of working wash buffer (WWB), 
resuspended, zip-spun and the supernatant removed and discarded. The WWB wash 
step is repeated if required. The silica beads were washed with 150 IJL of 100% 
ethanol. The silica beads were resuspended, zip-spun until clear and the supernatant 
removed and discarded. The DNA/silica bead suspension was then air-dried and 
resuspended using 150 IJL ddH20 via vortexing. The samples were subsequently 
incubated at 56°C for one hour and stored at 4°C for short term usage and -20°C for 
long term storage. Prior to each amplification, the extracts were incubated for 
approximately 30 minutes at 56°C and centrifuged at 13,000 r.p.m. for one minute (Hoss 
1993). 
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2.2.2 Genetic Amplification 
Amplification was performed using the polymerase chain reaction (PCR) in order 
to amplify specific regions of interest as defined by forward and reverse primers. An 
initial multiplex PCR, a hemi-nested PCR, and a single base extension PCR were used 
to amplify the five polymorphisms of interest. Primers were designed (Table 3) and 
purchased from Operon (Alameda, CA, USA). Oligonucleotides were delivered and re-
suspended by adding the calculated volumes of deionized water. A working solution at 
100 !JM was prepared and aliquoted. 
Table 3- Primer Information for Mulltiplex PCR 
Gene Forward Primer (5' --t3') Primer Reference GeneBank Position 
T~Ee Accession# 
CBS-1 T ATTGGCCACTCCCAT AA TAGAA Forward (Barbaux AF042836 17974-eta/. 2000) 17996 
CBS-2 CGGCTCTGCGAGGATGGACCCTT Reverse (Barbaux AF042836 18101-eta/. 2000) 18079 
MS-A TGTTCCCAGCTGTTAGATGAAAATC Forward (Barbaux AL359259 43622-eta!. 2000) 43646 
MS-B AGTCACATTAAAAACAAGCAAAA Reverse (Barbaux AL359259 43762-eta/. 2000) 43740 
MTHFR-0 GAATGTGTCAGCCTCAAAGAAAAG Reverse (Barbaux AY338232.1 8790-eta/. 2000) 8767 
MTHFR-1 AGGGAGCTTTGA GGCTGACCTGAA Forward (Barbaux AY338232.1 8694-eta/. 2000) 9717 
MTHFR-E GGAGCTGCTGAAGATGTGGGGGG Forward (Barbaux AY338232.1 10608-eta/. 2000) 10630 
MTHFR-D GTAAAGAACAAAGACTTCAAAGAC Reverse (Barbaux AY338232.1 10677-eta/. 2000) 10654 
MTRR-F1 GCTACACAGCAGGGACAGGC Forward This study AF121202 4175-4195 
MTRR-R1 GTAACGGCTCTAACCTTATCGG Reverse This study AF121202 4293-4272 
2.2.2.1 Multiplex Polymerase Chain Reaction 
The PCR setup was performed under sterile conditions to prevent contamination 
and performed in low light conditions on ice to prevent reagent and DNA extract 
84 
degradation. Reactions with a 25 !JL volume were aliquoted into 0.2 ml tubes from a 
prepared mastermix (Table 4) .. 
The cycling parameters were as follows: two minutes of initial hot start 
denaturation at 94·c followed by 30 cycles of denaturation for one minute at 94·c, one 
minute of annealing at 6o·c, and two minutes extension time at 72·c. For the ancient 
samples, the number of cycles was increased to 45. 
Table 4- Initial Multiplex PCR ampllification concentrations and volumes 
Reagent Initial Concentration Final Concentration 
PCR buffer 10 X 1 X 
dNTP 10 mM 0.2 mM 
MgCb 50 mM 2.0 mM 
CBS-1 10 !JM 0.06 !JM 
CBS-2 10 !JM 0.06 !JM 
MS-A 10 !JM 0.1 !JM 
MS-B 10 !JM 0.1 !JM 
MTHFR-1 10 !JM 0.032 !JM 
MTHFR-0 10 !JM 0.032 !JM 
MTHFR-E 10 !JM 0.072 !JM 
MTHFR-D 10 !JM 0.072 !JM 
MTRR-F1 10 !JM 0.16 !JM 
MTRR-R1 10 !JM 0.16 !JM 
Platinum®Taq 5 U/!JL 1.25 U 
DNA extract 
ddH20 















0.2-18.63 !JL (ancient) 
Brought up to 25 !JL 
After amplification, 6-7 IJL of the PCR product and 3 !JL of 6 X loading buffer was 
mixed and electrophoresed on a 6% polyacrylamide gel (PAGE) (Appendix- B). The 
electrophoresis tank was filled with 1 X TBE running buffer and the gel was run for 30 
minutes at 135 volts. The PC:R products were visualised using ethidium bromide 
staining and photographed on a UV-B trans-illuminator. The size of the band was used 
to interpret the results (Table 5). 
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Amplicon Size (bp) 
141 
128 (without insertion) 




2. 2. 2. 2 Hemi-nested Polymerase Chain Reaction 
A hemi-nested PCR was performed on degraded or LCN DNA samples to 
increase sensitivity and specifiicity. Prior to the hemi-nested PCR, the remaining PCR 
products were purified using DyeEx™ spin columns (Qiagen, Maryland, USA) following 
the manufacturer's protocol (Appendix- C). The hemi-nested PCR was optimised on 
the modern DNA sample (Table 6 before being applied to the degraded and LCN DNA 
samples. 
Table 6 - Primer Information for Hemi-nested Multiplex PCR 
Gene Forward Primer (5'----'»3') Primer Reference GeneBank Position 
Tlee Accession# 
CBS-2 CGGCTCTGCGAGGATGGACCCTT Reverse (Barbaux AF042836 18101-et at. 2000) 18079 
CBS-3 GCTTTTGCTGGCCTTGAGCC Forward This study AF042836 18019-18036 
MS-A TGTTCCCAGCTGTTAGATGAAAA TC Forward (Barbaux AL359259 43622-et at. 2000) 43646 
MS-C CAAGCAAAATCTGTTTCTACCACTTAC Reverse This study AL359259 43721-43748 
MTHFR-0 GAATGTGTCAGCCTCAAAGAAAAG Reverse (Barbaux AY338232.1 8790-et at. 2000) 8767 
MTHFR-2 GCTGACCTGAAGCACTTGAAGG Forward This study AY338232.1 8707-8738 
MTHFR-D GTAAAGAACAAAGACTTCAAAGAC Reverse (Barbaux AY338232.1 10677-et at. 2000) 10654 
MTHFR-F TGGGGGGAGGAGCTGACC Forward This study AY338232.1 10624-10641 
MTRR-F1 GCTACACAGCAGGGACAGGC Forward This study AF121202 4175-4195 
MTRR-R2 GCAGAAAATCCATGTACCACAGC Reverse This study AF121202 4258-4236 
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Hemi-nested PCR amplifications were prepared from a mastermix and aliquoted 
into 25 ~L reaction volumes like the initial multiplex PCR amplification (Table 7). 
Table 7- Hemi-nested PCR amplification concentrations and volumes 
Reagent Initial Concentration Final Concentration 
PCR buffer 10 X 1.6 X 
dNTP 10 mM 0.2 mM 
MgCb 50 mM 1.8 mM 
CBS-2 10 ~lVI 0.1 ~M 
CBS-3 10~1\11 0.1~M 
MS-A 10 ~M 0.12 ~M 
MS-C 10~1\11 0.12~M 
MTHFR-0 10 ~lVI 0.08 ~M 
MTHFR-2 10 ~M . 0.08 ~M 
MTHFR-F 10 ~lVI 0.08 ~M 
MTHFR-D 10 ~lVI 0.08 ~M 
MTRR-F1 10 ~M 0.1 ~M 
MTRR-R2 10 ~lVI 0.1 ~M 
Platinum®Taq 5 U/~L 1.25 U 
Purified PCR product -
ddH20 
















Brought to 25 ~L 
The samples were then placed in the thermal cycler under the following 
parameters: 2 minutes of initial denaturation at 94°C (Hot Start) followed by 30-45 
cycles of denaturation for 1 minute at 94°C, 1 minute of annealing at 58°C, and 2 
minutes extension time at 65°C. 
After amplification, 6-7 ~L of the PCR product and 3 ~L of 6 X loading buffer was 
mixed and then electrophoresed on a prepared 6% polyacrylamide gel (PAGE) 
(Appendix- B). The electrophoresis tank was filled with 1 X TBE running buffer and the 
gel was run for 30 minutes at 135 volts. The PCR products were then visualised using 
ethidium bromide staining and photographed on a UV-B trans-illuminator (Table 8). 
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Table 8- Hemi-nested PCR amplification Target sizes 
Polymorphism Primers (F/R) Amplicon Size (bp) 
MS A2756G MS-A/C: 126 
MTHFR C677T MTHFR-2/0 84 
CBS 844ins68 CBS-3/:2 83 
MTHFR A1298C MTHFR-F/0 83 
MTRR A66G MTRR-F1/R2 54 
2.2.2.3 Snapshot Polymerase Chain Reaction 
Prior to the SNaPshot™ PCR, the remaining PCR products were purified using 
DyeEx™ spin columns (Qiagen, Maryland, USA) following the manufacturer's protocol. 
A second purification step was performed by transferring 15 j.JL of the purified PCR 
product to a sterile 0.2 ml tube in which 5 U SAP (Waterston eta/.) (Pro mega, 
Madison, Wisconsin, USA) and 6 U Exonuclease I (EX01) (Biolabs, Ipswich, MA, New 
England) was added. The samples were incubated at 3iC for 60 minutes followed by 
20 minutes at 8o·c to inactivate the enzymes. Following purification the SNE-PCR was 
performed on the digested and purified PCR products (Table 9). 






























1 0680-1 0650 
4190-4212 
To prepare the SNE-PCR, 0.3-0.5 j.JL of the digested PCR product was mixed 
with 4.5 j.JL SnaPshot™ PCR Ready Reaction mix (Applied Biosystems, Foster City, 
CA, USA), 1 j.JL of each 10 mM extension primer (Table 9) adding ddH20 to bring the 
final volume to 10 j.Jl. This mixture was placed in the thermal cycler under the following 
parameters: 25 cycles of 96·c for 10 seconds, so·c for 5 seconds, and 6o·c for 30 
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seconds. When completed, 1 U of SAP was added and the reaction mixture was 
incubated for 60 minutes at 3TC and 20 minutes at 80°C to deactivate the enzymes. 
2.2.3 Data Analysis 
The samples were elecltrophoresed on the ABI Prism 3100 Genetic Analyser 
(Applied Biosytems) at the Paleo-DNA Laboratory. Prior to loading, 9 ~L HI-DI 
formam ide and 0.1 ~L of Genelscan TM 120 uz™ size standard were added to 1 ~L of 
reaction mixture. The samples underwent denaturation by heating to 95°C for 5 
minutes. Products generated were then analysed with GeneScan® Analysis Software 
in which genotypes of either homozygotes or heterozygotes were determined based on 
the location and fluorescence color of peaks (Table 10 and Table 11 ). 
Table 10- Extension primers for thH multiplex detection of the five markers 
Locus Primer sequence Length Reference 










MTH FR C677T GAAGGTGTCTGCGGGAG 
MTHFR A1298C GAGGTAAAGAACAAAGACTTCAAAGACACTT* 
CBS 844ins68* TGCAGATCATTGGGGTGGATC 
MTRR A66G CAGGCAAAGGCCATCGCAGAAGACAT 
*This is the only reverse primer. 



























* Brackets indicate the nucleotide detected by SNE due to a reverse primer being used. 
** The CBS marker is an insertion, + indicates the presence of the insertion while -
indicates its absence. 
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3 Results 
3.1 Gel Electrophoresis 
3.1.1 Initial Multiplex 
Optimised annealing temperature, magnesium chloride (MgCI2) and Taq DNA 
polymerase concentrations were determined by performing gradient PCRs. The optimal 
condition was determined visually. Densitometry is able to identify the quantity and thus 
most efficient amplification but visually I was able to identify the presence of non-
specific product and other PCR artefacts. 
The temperature gradient PCR for the optimisation of each of the singleplex 
reactions were performed first so that the optimal conditions could be determined. The 
optimal annealing temperature for each genetic target was determined (Figures 22-26). 
The temperature gradient PCR for the MTHFR C677T (Figure 22) target and the CBS 
(Figure 25) target produced a !large optimal temperature range from 58-62°C while the 
others all produced a smaller optimal temperature range between 60-61 OC (Figure 23, 
24, and 26). 
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Figure 22 - Determination of optimal annealing temperature for the MTHFR C677T mutation (Initial 
PCR) 
The product is at 97bp. Lane 1) 58.1°C; 2) 58.2°C; 3) 50bp Molecular marker; 4) 
58.6°C; 5) 59.3°C; 6) 60.2°C; 7) 61.3°C; 8) 62.4 OC; 9) 63.5°C; 1 0) 64.5°C; 11) 65.4 OC; 
12) 66.1°C; 13) 66.4°C; 14) Empty and 15) Empty. 
Figure 23- Determination of optimal annealing temperature for the MTHFR A1298C mutation 
(Initial PCR) 
The product is at 73bp. Lane 1) Empty; 2) Empty; 3) 66.4 OC; 4) 66.1 OC; 5) 65.4 OC; 6) 
64.5°C; 7) 63.5°C; 8) 62.4°C; 9) 61.3°C; 1 0) 60.2°C; 11) 59.3°C; 12) 50bp Molecular 
marker; 13) 58.6°C; 14) 58.2°C; 15) 58.1°C. 
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Figure 24- Determination of optimal annealing temperature for the MS A2756G mutation (Initial 
PCR) 
The product is at 141 bp. Lane 1) 50bp Molecular marker; 2) 58.1 ·c; 3) 58.2·.c; 4) 
58.6·c; 5) 59.3·c; 6) 6o.2·c; 7) 61.3·c; 8) 62.4·c; 9) 63.5·c; 1 o) 64.5·c; 11) 65.4 ·c; 
12) 66.1 ·c; 13) 66.4 ·c; 14) Empty and 15) Empty. 
A gradient temperature PCR will identify which targets may be prone to the 
generation of non-specific product. Non-specific amplification products were observed 
predominantly in the MS (Figure 24) and the MTRR (Figure 26) amplifications. These 
products were produced below 6o·c. All of the other targets demonstrated some 
degree of primer dimer formations but not at the level that would interfere with the 
efficiency of the PCR. 
Figure 25- Determination of optimal annealing temperature for the CBS 844ins68 mutation (Initial 
PCR) 
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The product size is 128bp. Lane 1) 58.1 OC; 2) 50bp Molecular marker; 3) 58.2°C; 4) 
58.6°C; 5) 59.3°C; 6) 60.2°c; 7) 61.3·c; a) 62.4 ·c; 9) 63.5oc; 1 o) 64.5oc; 11) 65.4 oc; 
12) 66.1°C; 13) 66.4°C; 14) Empty and 15) Empty. 
Figure 26 - Determination of optimal annealing temperature for the MTRR A66G mutation (Initial 
PCR) 
The product is 119bp. Lane 1) Empty; 2) 50bp Molecular marker; 3) 55.0°C; 4) 55.2°C; 
5) 55.TC; 6) 66.6°C; 7) 57.TC; 8) 59.0°C; 9) 60.4°C; 10) 61.WC; 11) 63.rC; 12) 
64.2°C; 13) 65.o·c; 14) 65.4·c; 15) Empty. 
A gel was performed to compare the amplicon sizes to one another (Figure 27). 
This gel confirms that all of the amplicons can be resolved from one another, there is no 
size overlap of any of the amplicons and all of the amplicons are the expected sizes. 
This gel shows each singleplex amplicon side by side and will help to identify the 
expected size of each band in the multiplex reaction in relation to each other. 
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Figure 27- Initial PCR Singleplexes, 
The product sizes are the following: CBS 844ins68 128bp; MS A2756G 141 bp; MTHFR 
C677T 97bp; MTHFR A 1298C 73bp. Lane 1) 50bp Molecular marker; 2) Extraction 
Negative; 3) PCR Negative; 4) CBS 844ins68; 5) CBS 844ins68; 6) CBS 844ins68; 7) 
MS-A2756G; 8) MS-A2756G; 9) MS-A2756G; 1 0) MTHFR C677T; 11) MTHFR C677T; 
12) MTHFR C677T; 13) MTHFR A1298C; 14) MTHFR A1298C and 15) MTHFR 
A1298C. 
The next step of the optimisation is to add all of the primer sets together in a 
··single multiplex reaction. Since all of the singleplex reactions were optimal at 60°C then 
this temperature was chosen for the first stages of the initial multiplex optimisation. The 
primers were added in equimolar concentration and then each primer concentration was 
changed depending on the relative intensity of the product band. The optimisation of 
primer concentration took many PCR reactions and gels to determine (Figure 28, 35, 37 
and many more not shown). An example of this optimisation process is shown in Figure 
28 where one of the gels for primer concentration changes is shown. Two experiments 
are shown in triplicate on the left and on the right hand side of the gel. Two of the 
bands on left hand side of the gel are faint (lane 4: 141 and 128 bp) while on the right 
the concentration of the primers have been increased to produce a relatively equal 
intensity of the product band. The optimal concentration of all of these primers was 
determined (Table 4). 
94 
Figure 28- Determination of optimal primer concentrations for the initial Multiplex 
The product sizes for each target are: MS 2756G 141 bp; CBS 844ins68 128bp; MTRR 
A66G 119bp; MTHFR C677T 97bp; MTHFR A 1298C 73bp. Lane 1) Empty; 2) 50bp 
Molecular marker; 3) to 5) Initial multiplex; 6) PCR Negative; 7) Empty; 8) to 1 0) Initial 
multiplex; 11) PCR Negative; 12) to 15) Empty. 
3.1.2 Hemi-nested Multiplex 
The optimisation of the hemi-nested PCR followed by using the initial PCR 
products of the control DNA. Again all of the temperature gradient singleplex reactions 
were performed (Figure 29-33). All of the singleplex targets except the MTHFR C677T 
target (Figure 29) produced non-specific product and smearing (Figure 30-33). 
However, this was not of such great concern as this multiplex in the final procedure will 
be performed as a hemi-nested PCR using the PCR product from the initial multiplex. 
All of the non-specific product and smears would be eliminated due to the successful 
competition between specific template and non-specific product as none of the non-
specific product will be present from the initial multiplex reaction. The optimal annealing 
temperature for the hemi-nested PCR was determined to be 58°C. 
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Figure 29- Determination of optimal annealing temperature for the MTHFR C677T mutation (Hemi 
nested) 
The amplicon size is 84bp. Lane 1) 50bp Molecular marker; 2) Empty; 3) Empty; 4) 
55.0'C; 5) 55.1'C; 6) 55.4'C; n 55.8'C; 8) 56.4'C; 9) 57.0'C; 10) 57.7'C; 11) 58.4'C; 
12) 59.1 'C; 13) 59.6'C; 14) 60.0'C; 15) 60.3'C. 
Figure 30 - Determination of optimal annealing temperature for the CBS 844ins68 mutation (Hemi-
nested) 
The amplicon size is 83bp. Lane 1) Empty; 2) 100bp Molecular marker; 3) 57.0'C; 4) 
57.2'C; 5) 57.7'C; 6) 58.6'C; 7) 59.8'C; 8) 61.1 'C; 9) 62.5'C; 1 0) 63.8'C; 11) 65.1 'C; 
12) 66.2'C; 13) 67.0'C; 14) 67.5'C; 15) Empty. 
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Figure 31 -Determination of optimal annealing temperature for the MTHFR A1298C mutation 
(Hemi-nested) 
The amplicon size is 54bp. Lane 1) 100bp Molecular marker; 2) 54.9.C; 3) 55.2.C; 4) 
56.o·c; 5) 57.4 ·c; 6) 59.1 ·c; 7) 61.1 ·c; 8) 62.s·c; 9) 63.s·c; 1 O) 65.1 ·c; 11) 66.2·c; 
12) 67.o·c; 13) 67.5·c; 14) and 15) Empty. 
Figure 32 - Determination of optimal annealing temperature for the MTRR A66G mutation (Hemi-
nested) 
The amplicon size is 74bp. Lane 1) Empty; 2) 50bp Molecular marker; 3) 55.o·c; 4) 
55. rc; 5) 55.4 ·c; 6) ss.s·c; 7) 56.4 ·c; 8) 57.o·c; 9) 57.TC; 1 o) 5s.4·c; 11) 59.1 ·c; 
12) 59.6·c; 13) 6o.o·c; 14) 6o.3·c; 15) Empty. 
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Figure 33- Hemi-nested singleplex of MS A2756G 
The amplicon size is 126bp. Lane 1) 50bp Molecular marker; 2) to 6) MS A2756G; 7) 
PCR Negative; 8) Empty; 9) to 13) MS A2756G; 14) PCR Negative; 15) Empty. 
Once the singleplex reactions were optimised, a gel was performed to compare 
each of the resulting PCR products (Figure 34; not all products shown on this gel). This 
determined that each band could be resolved and helped to identify each band in the 
multiplex reaction in relation to each other. Throughout this research, contamination 
was observed (Figure 34 ). On the gel in the Figure 34 in lane 5 and 13, contamination 
was observed; however, this was in the optimisation stages. Lane 5 shows 
contamination producing a band at exactly the expected size for that amplicon. This 
band was produced by contamination of that PCR from modern DNA while lane 13 
shows a smear and faint bands above and below the specific amplicon size. This 
contamination could be from modern DNA but has produced a great deal of non-specific 
product and could be from another animal source. It is more likely a mixture of 
background laboratory contamination of human and animal DNA as the specific band of 
interest is present though faint. 
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Figure 34- Hemi-Singleplex 
The amplicon sizes are: MTRR A66G F1/R2 74bp; MSA2756G-A/C 126bp; CBS 
844ins68 2/3 83bp. Lane 1) 50bp Molecular marker; 2) Empty; 3) and 4) MTRR A66G; 
5) PCR Negative; 6) Empty; 7) and 8) MS A2756G; 9) PCR negative; 1 0) Empty; 11) 
and 12) CBS 844ins68; 13) PCR negative;14) and 15) Empty. 
Like the first multiplex reaction, the primer concentrations for the hemi-nested 
multiplex PCR had to be optimised. Figure 35 and 37 presents examples of this 
optimisation process. The optimal primer concentrations were determined (Table 7). 
Comparison of the initial multiplex results and the hemi-nested multiplex results can be 
compared in Figure 35 and 37. 
Figure 35- Determination of primer concentrations in hemi-nested multiplex and initial multiplex 
PCR 
The hemi-nested multiplex PCR sizes are: MS 2756G 126bp; MTHFR C677T 84bp; 
CBS 844ins68 83bp; MTRR A66G 7 4bp; MTHFR A 1298C 54bp and the initial multiplex 
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PCR sizes (MS 2756G 141bp; CBS 844ins68 128bp; MTRR A66G 119bp; MTHFR 
C677T 97bp; MTHFR A1298C 73bp. Lane 1) Empty; 2) 50bp Molecular marker; 3) to 8) 
Hemi-nested multiplex; 9) PCR Negative; 1 0) Empty; 11) to 13) Initial multiplex; 14) and 
15) Empty. 
In both multiplex reactions, some of the reagents were tested under a 
concentration gradient PCR. The optimal MgCb, Taq DNA polymerase and buffer 
concentrations were determined to be 2.0 mM, 1.25 U and 1 X respectively for the initial 
PCR and 1.8 mM, 1.25 U and 1.6 X respectively for the hemi-nested PCR. An example 
of one of these gradient PCRs is presented as Figure 36 where the DNA polymerase 
concentration gradient is presented. The optimal concentration for the DNA polymerase 
was found to be 1.25 U for both reactions. 
Figure 36- Determination of optiimal Taq and template concentrations - Hemi-nested Multiplex 
The product sizes for each target are the following: MS 2756G 126bp; MTHFR C677T 
84bp; CBS 844ins68 83bp; MTRR A66G 7 4bp; MTHFR A 1298C 54bp. Lane 1) 50bp 
Molecular marker; 2) to 6) Decreased Taq concentration; 7) PCR negative; 8) Empty; 9) 
to 14) Template gradient; 15) Empty. 
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Figure 37- Optimal primer concentrations determination of initial and hemi-nested multiplex 
The amplicon sizes of the initial multiplex are: MS 2756G 141 bp; CBS 844ins68 128bp; 
MTRR A66G 119bp; MTHFR C677T 97bp; MTHFR A1298C 73bp while the amplicon 
sizes for the hemi-nested multiplex PCR are MS 2756G 126bp; MTHFR C677T 84bp; 
CBS 844ins68 83bp; MTRR A66G 74bp; MTHFR A1298C 54bp. Lane 1) Empty; 2) 
25bp Molecular marker; 3) to !5) Initial multiplex; 6) Initial multiplex PCR negative; 7) to 
1 0) Hemi-nested multiplex; 11) Hemi-nested multiplex PCR negative; 12) to 15) Empty. 
3.2 Sequencing Data of Modern Sample 
The following sequencing results consist of the data obtained from the modern 
known sample which was subsequently used to optimise the methodology. The 
genotype of the modern sample was determined through sequencing and SNE (Table 
12). From the sequence data, the genotype at each loci can be determined (Figure 38, 
40, 42, 44, and 46). Each of the sequences generated were aligned to the 
corresponding sequence in GeneBank (Figure 39, 41, 43, 45, and 4 7). 
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3.2.1 Cystathionine beta-synthase CBS 844ins68 
60 70 80 90 10 
J:., T G p, T T G G G G T G G ,",.T C •.:: G ,"', ,',G G G T C Co'. T G G T C G C' ,-c_o .c\0 C~ G G 
Figure 38- CBS 844ins68 genera1:ed sequence for modern sample and sequence alignment with 
GeneBank Assession#AF042836.1 (with highlighted SNP) 
The genotype for the CBS target in the modern sample is homozygote without 
the insertion (Figure 38 and 39). The insertion, if present, would have an extra 68 bp of 
sequence inserted at the point where the arrow indicates (Figure 39). 
~-
AF042836.1 ATCATTGGGGTGGA TC :c ~GAAGGGTCCATCCTCGCAGAGCCG 
Control Sample ATCATTGGGGTGGA TC ~ CGAAGGGTCCATCCTCGCAGAGCCG 
Figure 39 -The sequence alignment of the modern control sample to the reference sequence of 
Cystathionine beta-synthase. 
The reference sequence is from GeneBank with accession number #AF042836.1. The 
arrow indicates where the insertion if present would be found. The box indicates the 
target for the SNE detection. 
3.2.2 Methionine Synthase MS A2756G 
40 60 70 80 
Gi:.,T/',T T AG.".C.".G G GCAT TC T G ,6,GTCTG TG A GOT AA,GT GOT AG AA".GAG i·,T 
Figure 40 - MS A2756G generated sequence for modern sample and sequence alignment with 
GeneBank Assession#AL359259 (with highlighted SNP) 
The sequence generated for the modern sample from the MS amplicon identified 
the modern sample as a homozygote (M) (Figure 40 and 41 ). However, the SNE 
results indicated that this sample was a heterozygote (AG) (Table 12). The sequencing 
was replicated numerous times and still produced a homozygote indicating some of the 
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errors that can occur when using one method alone and the competition that occurs 
between both alleles of the target region. 
~ 
AL359259 GATATTAGACAG( lA CCATTATGAGTCTCTCAAGGTAAGTGGTAG 
Control Sample GATATTAGACAGC lA CCATTATGAGTCTCTCAAGGTAAGTGGTAG 
Figure 41 -The sequence alignmEmt of the modern control sample to the reference sequence for 
Methionine Synthase 
The reference sequence is from GeneBank with accession number #AL359259. The 
box indicates the target for the SNE detection. 
3.2.3 Methionine synthas•~ reductase MTRR A66G 
~ ~ ~ ~ 
•6• T T G T G i',G C A G c; T G T GOG T AC,"'. T G G AT T T T C T G C AG AT C T T C 
Figure 42 - MTRR A66G generated sequence for modern sample and sequence alignment with 
GeneBank Assession#AF121202 (with highlighted SNP) 
A heterozygous genotype (AG) was identified for the modern sample at the 
MTRR loci. The sequence here indicates two bases overlapping the A and the G 
present on the electropherogram (Figure 42). This result was confirmed by the SNE 
detection (Table 12). The R in the alignment (Figure 43) denotes the presence of the A 
and the G in that nucleotide position. 
AF121202 Al G lf"GTGAGCAAGCTGTGGTACATGGATTTTCTGCAGATCTTC 
Control Sample Al R~GTGAGCAAGCTGTGGTACATGGATTTTCTGCAGATCTTC 
Figure 43- The sequence alignment of the modern control sample to the reference sequence for 
Methionine Synthase Reductase 
The reference sequence is from GeneBank with accession number #AF121202. The 
box indicates the target for thE3 SNE detection. The R denotes the presence of an A or a 
G in that position, representing a heterozygote. 
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3.2.4 5, 1 0-Methylenetetrahydrofolate reductase MTHFR C677T 
20 30 40 50 
G T C T GC G G G ,c.,o C G i'>T T T (\'-',T C' ,",T C i·.C G C~ i'.G C T T T T C T T T G 
Figure 44- MTHFR C677T generated sequence for modern sample and sequence alignment with 
GeneBank Assession# AY338232.1 (with highlighted SNP) 
For the MTHFR C677T marker, the modern sample was determined to be a 
heterozygote (CT). The electropherogram shows two nucleotides present (black 







Figure 45- The sequence alignm•mt of the modern control sample to the reference sequence for 
5, 10-Methylenetetrahydrofolate mductase C677T polymorphism 
The reference sequence is from GeneBank with accession number #A Y338232.1. The 
box indicates the target for the SNE detection. The Y denotes the presence of a C or a 
Tin that position, representing a heterozygote. 
3.2.5 5, 1 0-Methylenetetrahydrofolate reductase MTHFR A 1298C 
30 40 50 
"J·, G T OOT o::::rTT T Gi•,i·, GGT C TIT T GGTIT C TIT T 
Figure 46- MTHFR A1298C generated sequence for modern sample and sequence alignment with 
GeneBank Assession# AY338232.1 (with highlighted SNP) 
The modern sample was identified as a heterozygote for the MTHFR A1298C 
polymorphism. In the sequence electropherogram, the presence of an A and a G can 
be seen (black highlighted section) (Figure 46). These two nucleotides are represented 




AY338232.1 GTGAAG J'\J ~GTGTCTTTGAAGTCTTTGTTCTTT 
Control Sample GTGAAC: R ~GTGTCTTTGAAGTCTTTGTTCTTT 
-
Figure 47- The sequence alignment of the modern control sample to the reference sequence for 
5, 1 0-Methylenetetrahydrofolate ntductase A 1298C polymorphism 
The reference sequence is from GeneBank with accession number #A Y338232.1. The 
box indicates the target for the SNE detection. The R denotes the presence of an A or a 
Gin that position, representin~) a heterozygote. 
3.3 Snapshot Data 
Table 12- Modern Sample Genoty e 
Genotype Sample 
Name MTRR A66G MTHFR C677T CBS 844ins68 MTHFR A 1298C MS A2756G 
1-LC AG CT -1- AC AG 
*verified sequencing 
The known modern control exhibited a heterozygous genotype for mutations 
MTRR A66G, MTHFR C677T, MTHFR A1298C and MSA2756G using the SNE typing 
method (Table 12). The CBS 844ins68 was the only mutation to be observed in a 
homozygous state(-/-) with no insert in either allele present (Table 12). 
Table 13- Experimental!~ Dearaded Samples Genot~pes 
Sample Genotype 
Name MTRRA66G MTHFR C677T CBS 844ins68 MTHFR A 1298C MS A2756G 
2-TJ AG CT -I- AC AG 
3-RS AG CT +I- AC AG 
4-AL AG CT -I- AC AG 
5-RCP AG CT -1- AC AG 
6-AT AG CT +I- AC GG 
7-AH AG CT -I- AC AG 
8-LI (1/10) AG CT -I- AC AG 
9-CB (1/1 0) AG CT -I- AC AG 
10-R (1/10) AG CT -I- AC AG 
11-CH AG CT -I- AC M 
Full genotypes were dE~termined for all of the experimentally degraded samples 
(Table 13). The experimentally degraded samples were heterozygous for the MTRR 
A66G (AG); MTHFR C677T (CT) and the MTHFR A1298C (AC) mutation. In the case 
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of the MS A2756G mutation, all samples were heterozygous (AG) except two samples 
which were homozygous: sample 6 (GG) and sample 11 (AA). The CBS 844ins68 
insertion was observed in a heterozygous state ( +/-) in samples 3 and 6. 
Table 14- Medical Archive Sam~les Genot~~es 
Sample Genotype 
Name MTRRA66G MTHFR C677T CBS 844ins68 MTH FR A 1298C MS A2756G 
12-AO AG CT -I- AC G 
13-001 AG CT +I- AC AG 
14-002 AG CT +I- AC AG 
15-JZ GG CT AC GG 
16-YB GG CT +I- AC G 
Most of the medical archive specimens produced full genotypes with the 
exception of samples 12, 15 and 16 which may have experienced allelic drop-out (MS 
A2756G and CBS 844ins68) (Table 14). Heterozygosity was observed for both MTHFR 
C677T and MTHFR A1298C mutations in all medical archive samples. The insertion 
allele (CBS 844ins68) was noted in three samples (sample 13, 14 and 16). In respect 
to the MTRR A66G mutation, two samples (samples 15 and 16) exhibited the mutant 
genotype (GG) while the other three samples were heterozygous (AG). The G allele 
was observed in all the samples either in heterozygous (AG) in samples 13 and 14; 
homozygous in sample 15. 
Table 15- Archeological Samples Genotypes 
Sample Genotype 
Name MTRR A66G MTHFR C677T CBS 844ins68 MTH FR A 1298C MS A2756G 
17-Burial #20 
18-Burial #37 G 
19-Burial #40 
20-Burial #41 CT 






Of the five archeological samples, only one sample (sample 21) produced a full 
genotype (Table 15). Possible allelic drop-out was observed in all the samples. One 
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G 
allele (G) was noted in the MTRR A66G and MSA2746G mutations in samples 18 and 
21; while the A allele was noted in samples 17, 19 and 20 for the MTHFR A 1298C 
mutation. Heterozygosity was observed in samples 20 and 21 for the MTHFR C677T 
mutation, samples 18 and 21 for the MTHFR A1298C mutation, as well as sample 21 
for the CBS 844ins68 mutation. It must be noted that the samples were replicated at 
least twice depending on the amount of sample available. The concentration of certain 
samples was not high enough to allow for many replicates. The multiple results were 




A novel methodology was successfully designed and optimised in which five 
mutations were detected simulltaneously in samples of various levels of degradation. 
Single nucleotide extension can be performed in two ways. It can be used directly on 
the DNA extracts or it can be used after an initial PCR of the desired target. By 
performing an initial PCR you are increasing the template concentration in relation to 
the DNA in the extract, thus increasing the sensitivity and the specificity of the SNE-
PCR. Direct SNE-PCR cannot be used on degraded or ancient DNA as sensitivity and 
specificity of the analytical procedure is critical to these studies. 
This method is not suitable for the detection of LCN DNA. Even though the 
technique is sensitive the LCN DNA may be in much lower concentration than can be 
reliably detected. These very low levels of DNA concentration can generate stochastic 
variation which will preferentially amplify different alleles and allelic or loci drop-out can 
occur (Gill 2001 ). This would result in inaccurate genotyping. These problems were 
encountered in this research. 
In order to overcome this challenge, in addition to an initial PCR to increase 
sensitivity and specificity a hemi-nested PCR was developed. A hemi-nested PCR is 
often quite successful in reducing or eliminating unwanted products while at the same 
time increasing specificity (Gibbs 1990; Mullis 1991; Mullis and Faloona 1987; Zhang 
and Ehrlich 1994; Zimmermann et at. 1994 ). This hemi-nested approach followed by 
SNE-PCR to increase sensitivity and specificity for degraded DNA was introduced by 
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Larcombe eta/. (2005). In this research one set of primers were designed to amplify the 
target region and a third primer was designed and optimised to perform a hemi-nested 
PCR which was then followed by the SNE-PCR. This was able to increase the 
sensitivity. However time did not permit the assessment of this three step 
methodological approach to overcome allelic drop-out. 
The initial PCR, hemi-nested PCR and SNE-PCR were designed as a multiplex 
to gain more information from each analysis and to help in the authentication of the 
degraded DNA results. The design and optimisation process began with the design of 
the primers 3'or 5'of the SNP of interest. In the case of the CBS gene it was a 68 bp 
insertion and so primers were designed to identify the difference between the presence 
and absence of the insertion by SNE. 
The design and optimisation of the initial PCR began with the design of the 
primers. For the initial PCR most of these primers were chosen from the literature 
(Table 3). All except for one set of primers for the MTRR target were chosen from the 
literature. All of the primers were tested using a computational simulator (Amplify™) 
(Appendix A) to determine their stability by avoiding the presence of secondary 
structures, primer-primer complementarity and calculate the melting temperature. The 
experimental annealing temperature was determined for the initial PCR. An initial 
multiplex PCR was performed of equimolar primer concentration including all five primer 
sets. Primer concentration adjustments were done to observe PCR products of equal 
intensity (Figure 27 and Figure 28). The primer concentration was increased for those 
genetic targets that produced a low intensity band and vice versa for the high intensity 
PCR products. MgCb, Taq DNA polymerase, and DNA template concentration gradients 
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were also performed to determine their optimal concentrations. Additives (i.e. DMSO, Q 
solution, BSA) were assessed to determine if the results could be improved. With the 
optimal concentrations and cycling parameters, the initial multiplex was optimised. 
Prior to a hemi-nested PCR, the PCR products from the initial PCR must be 
purified. Several purification methods were tested such as Qiaquick spin columns, DTR 
spin columns, HiYield, silica bead purification; EtOH purification; NucleoSpin Extract 
spin column. The DyeEx purification column was determined to be the most effective 
method of purification. The hemi-nestedmultiplex was optimised in the same fashion 
as the initial multiplex. Primers were designed and evaluated on the computer before 
purchase (Table 6). Annealinn temperature gradient singleplex PCRs were performed 
for each step, followed by a multiplex PCR containing equimolar primer concentrations. 
Primer, MgCb, buffer, Taq DNA polymerase, and template concentrations were also 
optimised with adjustments and gradients (Figure 36, Figure 35 and Figure 37). The 
use of additives such as 2%DMSO, betaine, and Q solution, were also applied with no 
success. Different types of DNA polymerase (Q Taq, Platinum Taq) were tried with no 
differences observed. Extension temperature gradients were performed and a 65°C 
temperature demonstrated the best results, for most multiplex reactions the optimal 
extension temperature is usually about soc lower than the regular PCR. 
The SNE primers were designed to ensure their product lengths would not 
overlap during data-analysis; the primers are separated by approximately 5bp in length 
(Table 1 0). As well possible genotypes had to be considered to avoid confusion during 
their interpretation. Each primer was tested individually and then combined at 
equimolar concentrations in a SNE multiplex PCR. The SNE multiplex PCR was 
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optimised with template volume, primer and SnaPshot™ reaction mixture at different 
concentrations. The optimisation of the SNE-PCR required the adjustment of primer 
concentrations and increase or decrease of template volume according to sample type 
(i.e. more DNA template for thE~ archeological samples). 
The optimisation of each method proved to be quite challenging. The presence 
of non-specific bands, amplification failure, primer interaction, preferential amplification, 
no detectable product, as well as a low yield of the desired product were some 
problems. This not only made the PCR less efficient, but also made analysis of the 
results more difficult. Adjustments of PCR components (i.e. primer concentration to 
overcome preferential amplification of specific targets) and parameters enabled their 
optimisation. It was essential during optimisation to maintain a balance between 
specificity and sensitivity. All three steps were optimised individually and then 
combined together to detect tt1e mutations of interest (Section 2.2). As each step 
progressed, the specificity of the method subsequently increased. Thus, the product of 
the previous step was used as template for the next step with new primers of different 
sequences that exhibited complete homology. 
Negative controls ensured that the results of the PCR amplifications were indeed 
from authentic DNA samples and not from PCR products of other samples that were 
amplified in the lab. A negative control was included for each step of the methodology 
and carried throughout the whole process. A total of four negatives were employed: an 
extraction negative, an initial PCR negative; a hemi-nested PCR negative; and a SNE-
PCR negative. These controls would detect exogenous DNA from the extraction step 
until the final amplification and aid in identifying at which step contamination occurred. 
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Contamination did occur durin!g optimization of the methodology however it was 
identified and addressed. 
With LCN and degraded samples, the allelic balance deteriorates and the chance 
of allelic drop-out is increased compromising interpretation (Dixon eta/. 2006). The 
difficulty of determining the homozygotes between allelic drop-out when analysing the 
results became the most challenging task. For this reason we cannot be certain that an 
individual is a true homozygote in the interpretation of the archeological samples (Table 
15). Allelic drop-out is common due to the degradation level of the sample. Gill eta/. 
(2000) suggest that duplication of each allele should be performed in order to 
adequately identify the genotype and because of stochastic variation, any apparent 
homozygote is considered a potential heterozygote. 
In some cases the primers had to be redesigned. This was usually because the 
primers interacted with other primers in the multiplex reaction mix but was also due to 
data interpretation. As each amplicon was fluorescently labelled it could be detected 
using capillary electrophoresis but each of the amplicons exhibited some degree of 
electrophoretic run mobility shift depending on the fluorescent label. This change in the 
detected size of each of the am pi icons caused difficulty in assigning the correct peaks. 
Shorter primers with poly-A tails added to modify the size of the primer and thus the 
mobility and separation on electrophoresis were evaluated. The primers with the poly-A 
tails produced less mobility shift and were slightly more reliable than the full length 
complimentary primers. 
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4.2 Application of Methodology 
In this project, a novel multi-step methodology was developed, to assess 
simultaneously the genotype of five targeted areas within a sample of variable levels of 
degradation. Once the steps involved were optimised. The final methodology included 
three amplification steps: an initial multiplex PCR, a hemi-nested multiplex PCR, and a 
multiplex SNE-PCR using the ABI Prism® SNaPshot™ kit followed by detection with 
capillary electrophoresis (FigUire 48). The most critical step was the purifications 
between each PCR reactions which can introduce contamination. 
Extraction/Purification 




The genotype of a known modern sample was determined and used during 
optimisation of the methodology. The genotype of the modern sample (Table 12) at the 
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MS A2756G marker exhibited differences between the sequencing and SNE-PCR 
results. The sequence results indicated a homozygote while the SNE-PCR indicated a 
heterozygote. This is due to preferential amplification in the sequencing reaction 
amplifying only one allele. The results of the SNE-PCR were determined to be more 
reliable. Full genotypes were determined for all of the experimentally degraded 
samples (Table 13). While most of the medical archive specimens produced full 
genotypes with the exception of samples 12, 15 and 16 which may have experienced 
allelic drop-out (MS A2756G and CBS 844ins68) (Table 14). The majority of 
archeological samples, with the exception of sample 21, produced partial profiles (Table 
15). This is to be expected due to the degradation of the samples. The different 
sample types demonstrated the test's sensitivity. As the sample's degradation 
increased, the more likely a partial profile would be detected. Applying a single base 
extension amplification directly on experimentally degraded DNA was determined to 
have failed 97% of the time (Beaulne 2004 ). This study demonstrates how a hemi-
nested PCR is more senstitive and specific compared to applying the test directly to 
DNA. The table below (Table 16) contains the determined success rates. 





Multiplex followed by SNaPshot™ 
Multiplex ht3mi-nested and SNaPshot™ 
Experimentally Direct SNaPshot™ 
degraded DNA Multiplex followed by SNaPshot™ 
Multiplex hemi-nested and SNaPshot™ 
Degraded DNA Direct SNaPshot™ 
Multiplex followed by SNaPshot™ 
Singleplex hemi-nested followed by SNaPshot™ 
Multiplex hemi-nested and SNaPshot™ 
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Success Rate 









20% (full profile) 
60% (partial profile) 
The challenge in determining an accurate degraded sample's genotype is 
differentiating between a true homozygote and allelic drop-out. It is for this reason that 
we cannot assume a homozygote is a true homozygote when it could possibly be 
heterozygote. Another difficulty experienced during genotype determination was the 
different mobility shift of the fluorescent tags. The red dye (T), was greatly displaced by 
up to 10bp; the blue dye (G) by -1 to 4bp; the green dye (A) by -2bp; while the black dye 
(C) showed no mobility shift. 
All the samples exhibited heterozygosity (CT) for the MTHFR C677T mutation 
(Table 13, Table 14, and Table 15). Vander Put eta/. (1995), Johanning eta/. (2002) 
and Kirke eta/. (2004) indicate that the NTD risk for heterozygous individuals is only 
slightly elevated over the wild type (CC). This mutation which is commonly found in 
approximately 35% in the Norih American population may predispose individuals to 
mild to moderate hyperhomocysteinemia when folate status is low (Christensen eta/. 
1999; Frosst eta/. 1995; Jacques eta/. 1996). However, this result in all the samples 
may simply be due to the low number of samples in the study. A more comprehensive 
genotyping study should be conducted with a larger number of samples including both 
control and individuals with a NTD and individuals with NTDs in the family. The 
increased risk of NTDs due to the presence of the MTHFR C677T mutation may be 
mitigated by an adequate level of folate on ones diet. The archeological samples 
(samples 20 and 21) were heterozygous for the MTHFR C677T mutation (Table 15) 
which may indicate that this mutation combined with dietary stress and lack of folate 
may explain the morphological manifestations consistent with SB. 
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All the experimentally dHgraded, medical archive samples, and two of the 
archeological samples (sample 18 and 21) contain the MTHFR A1298C heterozygous 
genotype (AC); while the rest of the archeological samples ( 17,19,20) exhibit the A 
allele at the MTHFR A1298C MTHFR mutation (Table 13, 14 and 15). De Marco eta/. 
(2002) determined that the prevalence of heterozygotes is increased among NTD 
patients and mothers. All the samples contained both heterozygote mutant allele 
(MTHFR 677CT/MTHFR 1298AC) which may indicate an increased risk for NTDs as 
demonstrated by Vander put et a/.(1998) and Weisberg eta/. (1998). 
In the case of the MS A2756G mutation, all the experimentally degraded samples 
contained the MS A2756G AG genotype except for samples 6 and 11, which had the 
MS A2756 GG and MS A2756G AA genotype respectively (Table 13). The medical 
archive samples consisted of two MS A2756G AG genotypes (samples 13 and 14), two 
MS A2756G GG genotypes (samples 12 and 15) and one sample with a MS A2756G G 
allele (Sample 16) for which the full genotype could not be determined (Table 14 ). The 
presence of the mutant allele demonstrates a deficiency in MS enzyme activity. 
All the experimentally degraded and medical archive samples (except two 
samples) were found to be heterozygote MTRR A66G AG for the MTRR polymorphism 
(Table 13). Samples 15 and 16 contained the homozygous GG mutant allele and 
samples 18 and 21 of the arct1eological samples contained the G allele, the full 
genotype could not be reliably ascertained in this sample (Table 13). Wilson eta/. 
(1999) detected a significant increase in NTD risk in heterozygotes of the MTRR 66G 
allele. 
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The CBS insertion was observed in 6 samples of the experimentally degraded, 
medical archive and archeological samples (3, 6, 13, 14, 16 and 21) (Table 13, Table 
14, and Table 15). A homozy~1ote for the CBS insertion was not observed in any of the 
samples analysed. The CBS insertion was not observed in combination with the 
MTHFR 677TT which would indicate an increased risk for NTDs. However, Relton eta/. 
(2004) did demonstrate that the CBS insertion may inflate the individual effect of the 
MTHFR variant. Most of the experimentally degraded and medical archive samples 
were homozygous without the insertion (Table 13 and Table 14 ). 
There is controversy regarding the linkage of these alleles to the risk of NTDs. 
There are no interpretations or conclusions presented here that link the specific 
genotype to NTDs. In my research the focus was on developing a methodology to 
analyse multiple mutant SNP that have been reported in the literature. Linking the 
genotype to NTDs would require larger sample numbers and more information on the 
part of the test subjects. 
The archeological samples (Table 15) containing the mutation alleles (either in 
heterozygous or 'homozygous' state) may indicate that these mutations combined with 
dietary stress and lack of folate support the morphological manifestations indicating 
spina bifida. This is evident in sample 21 which contains all the mutant alleles. 
A nutritional profile or the frequency of the alleles within the populations are not 
available for the archaeolgical samples and this study contains a relatively small sample 
size; therefore one must be cautious when drawing conclusions from these results 
regarding a link to NTDs. 
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5 Conclusion and Future Considerations 
In this research I developed a novel methodology to identify simultaneously the 
genotype of five genetic target areas that have been linked to NTDs. In the past, 
researchers have studied either one to three mutations linked to NTDs at a time. This 
methodology is the first of its kind to detect all five mutations simultaneously. This 
approach allows the association between the mutations and NTDs as well as the 
association between each mutation to be determined. This methodology can therefore 
assess the compound effect of each marker studied here that has been linked to NTDs. 
This method has also been assessed on samples exhibiting various levels of DNA 
degradation. Four different sets of samples exhibiting different amounts of degradation 
were analysed which tested the sensitivity and specificity of the technique. The 
designed method employs three steps of analysis: an initial multiplex PCR, a hemi-
nested multiplex PCR and a multiplex SNE-PCR. High quality DNA samples may not 
require the nested-PCR step, as this step is present to increase the sensitivity and 
specificity which is not require!d in high quality DNA samples. The experimentally 
degraded samples, medical archive samples and archeological samples were also 
analysed. Full genotypes wena generated for the experimentally degraded samples and 
the medical specimens however a full profile was generated for only one of the 
archeological samples. 
More work could be done to further optimise the methodology especially on the 
archeological samples. To complete method validation, this study must be repeated 
using more samples and to specifically determine the matrix effects, limitations, marker 
frequency, sensitivity and specificity. Sequencing of one individual for testing and 
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optimizing PCR conditions, and for estimating effectiveness of the methodology could 
not eliminate the possibility of allelic drop-out. Therefore, in order to validate the 
method, numerous clinical samples with and without NTDs should ideally be sequenced 
and SNE genotyped to ensure that all alleles are represented in the test. This would 
also allow the rate of allelic drop-out to be calculated and the methods success to be 
evaluated. Furthermore, the method should be applied to a larger sample size of 
modern individuals affected by, or related to an individual with spina bifida, or various 
forms of NTD from various ethnic backgrounds. Once validated, medically archived and 
degraded samples from areas with high prevalence of NTD can be analysed. Finally, 
my research demonstrates how this methodology can increase the sensitivity and 
specificity of the detection of disease related genetic mutations. My research could be 
further expanded to include other conditions associated with point mutations allowing 
the technique to be applied to archived medical specimens, medical screening, 
association studies, population mapping and evolutionary disease studies. In particular, 
my technique optimised for degraded DNA can analyse medical archived specimens: 
old blood donor cards, archived medical biopsies and archived clinical slides. The 
ultimate generation of medical pedigrees can aid clinical medicine in developing 
patient's family history and possible treatment. 
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Below are schematic representations of the initial and hemi-nested PCR primers 
and their genetic locations using the computational simulator. Figures 49 to 53 
represent the position of the primers and the lengths of the amplicons for both the initial 
and hemi-nested singleplexes along the target regions. The blue and red arrows 
indicate the forward and reverse primers respectively. The black rectangle represents 
the amplicon amplified and the primers used. For example, in Figure 49, primers CBS-1 
and CBS-2 are used for the initial PCR while primer CBS-2 and CBS-3 are used for the 
hemi-nested PCR producing an amplicon of 128 bp and 83 bp respectively. 
Fi ure 49- CBS Primer osition 
0 
--------------~------------~----~-------------+-~ 
128 bp; CBS-1 & CBS-2 -83 bp; CBS-3 & CBS-2 
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Fi ure 50- MS Primer Position 
0 
----------------------------------~----~------------~-------g 
141 bp; MS·A& MS·B -126 bp; MS·A & MS·C 
Fi ure 51 - MTHFR A 1298C Primer Position 




97 bp; MTHFR·1 & MTHFR-0 -84 bp; MTHFR- 2 & MTHFR·O 
Fi ure 52- MTHFR C677T Primer Position 
0 __________ _. ______________________ ~--------------------~~---~ 
• 0:: ..... I 
..i 
70 bp; MTHFR·E & MTHFR-D • 54 bp; MTHFR-F & MTHFR-D 
Fi ure 53- MTRR A66G Primer Position 
(;~;, 
--------------~-------------------------------------------- ~ 
1111~9-bp.; II!MT~R~R-~F~TRR-R1 -75 bp; MTRR-F1 & MTRR-R2 
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Appendix- 8 
Preparing a 6% Polyacrylamide gel {PAGE): 
1. Keep on ice at all times! 
Reagents 6 gels 12 gels 
5XTBE 10 ml 20 ml 
Acrylamide 6.25 ml 15 ml 
ddH20 33.25 ml 64 ml 
TEMED 45 !JL 90 !JL 
10% APS 450 pL 9oo eL 
2. Prepare 10% APS solution by mixing 0.1 g. ammonium persulfate (APS) to 1 
ml of ddH20. · 
3. Place a 125 ml Pyrex flask in an ice box and allow cooling for approximately 
20 minutes. 
4. Set up gel cassettes and combs ahead of time. 
5. Add reagents in the same order as they are listed above. 
6. Swirl the flask to mix the reagents. 
7. Fill gel cassettes from one corner using a transfer pipette. 
8. Ensure the bottom cassette groove is completely filled and does not have any 
air bubbles. 
9. Allow to solidify for 1 hour at room temperature, and then refrigerate. 
The flask was swirled once all the reagents were added to mix them. A transfer 
pipette was used to fill the gel cassettes until the liquid reached the bottom cassette 
groove. Caution was taken to ensure that no bubbles were in the cassette. A gel comb 
was placed in the cassette to form the wells. The gels were allowed to solidify for 1 
hour at room temperature then refrigerated. The electrophoresis tank was then 
prepared to run a gel. A prepared gel was taken and the strip of tape at the base of the 
cassette and the gel comb WE!re removed. The gel cartridge was placed in the 
electrophoresis tank. Spacer blocks or empty cartridges were used if it was only 
necessary to run one gel. The tank was filled with 1 X TBE running buffer until the wells 
were covered. 
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The wells were cleaned out with a transfer pipette to ensure that no particles 
were in the wells that could impede the running of the samples. 6-7 ~L of the amplified 
PCR products was mixed with 3 ~L of 6 X loading buffer. The loading buffer contains 
ficoll, a substance that allows the DNA sample to sink to the bottom of the well, and a . 
dye that allows visualisation of the sample being loaded. The 6 X loading buffer is 
prepared with the following reagents: 
Reagent Volume 
2.5% xylene cyanol 12 ~L 
2.5% bromophenol blue 12 ~L 
Ficoll (35%)* 432 !JL 
1 X TBE 544 ~L 
*Mix 3.5g of solid Fico II to 1 Oml ddH20. 
A standard molecular marker is loaded on each gel for band size discrimination. 
Loading and Running PAGE 
1. Obtain gel cartridges and remove strip of tape of gel comb. 
2. Place gel cartridge into gel apparatus. 
3. Fill apparatus with 1 X TBE running buffer. To make 1 X TBE buffer dilute 10 
X TBE (1 L ddH20; 108 g Tris; 55 g borate; 5.8 g EDTA). 
4. Make sure the runniing buffer covers the wells inside the apparatus and is 1/3 
full in the outside cartridge compartments. 
5. Clean out the wells with a transfer pipette. 
6. Fill out gel loading sheet. 
7. Fill in wells with sample and 6 X loading dye, and one lane of molecular 
marker. 
8. Set voltage at 135 V and time at approximately 30 minutes. 
9. After gel has run, stain with ethidium bromide (-15-20 minutes). 




DyeEx™ purification spin column Protocol 
1. Gently vortex the spin column to resuspend the resin. 
2. Loosen the cap of the column a quarter turn to ensure the seal is broken. This 
is necessary to avoid a vacuum inside the spin column. 
3. Snap off the bottom of the column and place the column into a collection tube 
(provided by manufacturer). 
4. Centrifuge at 2800 r.p.m. for 3 minutes. 
5. Discard the collection tube with the packing buffer. 
6. Place the column into a sterile 1.5 ml tube. 
7. Carefully add 10-20 11L of PCR solution (sequencing reaction) to the gel bed. 
8. **Pipette the sequencing reaction directly onto the center of the slanted gel-
bed surface. Do not allow the reaction mixture or the pipette tip to touch the 
sides of the column. The sample should be pi petted slowly so that the drops 
are absorbed into the gel and do not flows down the sides of the gel bed. 
Avoid touching the gel-based surface with the pipette tip. 
9. Centrifuge for 3 minutes at 2800 r.p.m .. 
10. Discard the column and kept the tubes. 
11. Dry the samples in a vacuum centrifuge for sequencing. No need for 
dessication for Snapshot™. 
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